<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003424.pub4" GROUP_ID="CF" ID="261201091810352101" MERGED_FROM="" MODIFIED="2016-08-22 10:33:20 +0100" MODIFIED_BY="Nikki Jahnke" REVIEW_NO="0053" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="12.0">
<COVER_SHEET MODIFIED="2016-08-22 10:33:11 +0100" MODIFIED_BY="Nikki Jahnke">
<TITLE>Drug therapies for reducing gastric acidity in people with cystic fibrosis</TITLE>
<CONTACT MODIFIED="2016-08-22 10:33:11 +0100" MODIFIED_BY="Nikki Jahnke"><PERSON ID="11758" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Sze May</FIRST_NAME><LAST_NAME>Ng</LAST_NAME><POSITION>Consultant Paediatrician and Paediatric Endocrinologist</POSITION><EMAIL_1>ngszemay@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Paediatrics</DEPARTMENT><ORGANISATION>Southport &amp; Ormskirk NHS Trust, Ormskirk District General Hospital</ORGANISATION><ADDRESS_1>Wigan Road</ADDRESS_1><CITY>Ormskirk</CITY><ZIP>L39 2AZ</ZIP><REGION>Lancashire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1695 656163</PHONE_1><FAX_1>+ 44 1695 656282</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2016-08-22 10:33:11 +0100" MODIFIED_BY="Nikki Jahnke"><PERSON ID="11758" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Sze May</FIRST_NAME><LAST_NAME>Ng</LAST_NAME><POSITION>Consultant Paediatrician and Paediatric Endocrinologist</POSITION><EMAIL_1>ngszemay@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Paediatrics</DEPARTMENT><ORGANISATION>Southport &amp; Ormskirk NHS Trust, Ormskirk District General Hospital</ORGANISATION><ADDRESS_1>Wigan Road</ADDRESS_1><CITY>Ormskirk</CITY><ZIP>L39 2AZ</ZIP><REGION>Lancashire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1695 656163</PHONE_1><FAX_1>+ 44 1695 656282</FAX_1></ADDRESS></PERSON><PERSON ID="z1605181239370745694702611289042" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Helen</FIRST_NAME><MIDDLE_INITIALS>S</MIDDLE_INITIALS><LAST_NAME>Moore</LAST_NAME><EMAIL_1>drhmoore@doctors.org.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Paediatrics</DEPARTMENT><ORGANISATION>Southport &amp; Ormskirk NHS Trust, Ormskirk District General Hospital</ORGANISATION><ADDRESS_1>Wigan Road</ADDRESS_1><CITY>Ormskirk</CITY><ZIP>L39 2AZ</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2016-08-18 14:44:31 +0100" MODIFIED_BY="Nikki Jahnke">
<UP_TO_DATE>
<DATE DAY="18" MONTH="8" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="12" MONTH="5" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="20" MONTH="8" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="8" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-08-18 14:44:12 +0100" MODIFIED_BY="Nikki Jahnke">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-08-18 14:44:12 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="18" MONTH="8" YEAR="2016"/>
<DESCRIPTION>
<P>A search of the Cystic Fibrosis and Genetic Disorders Group's Cystic Fibrosis Trials Register identified a single new reference to an already included trial (<LINK REF="STD-DiMango-2014" TYPE="STUDY">DiMango 2014</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-08-18 14:44:06 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="18" MONTH="8" YEAR="2016"/>
<DESCRIPTION>
<P>The review's previous co-author (Angelo Franchini) has stepped down and been replaced by Dr Helen Moore.</P>
<P>No new data were added at this update, so our conclusions remain the same.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-05-18 13:05:19 +0100" MODIFIED_BY="Nikki Jahnke">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-05-18 13:05:19 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="10" MONTH="7" YEAR="2014"/>
<DESCRIPTION>
<P>A search of the Cystic Fibrosis and Genetic Disorders Group's Trials Register identified a single new reference which has been included in the review (<LINK REF="STD-DiMango-2014" TYPE="STUDY">DiMango 2014</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-05-18 13:03:23 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="10" MONTH="7" YEAR="2014"/>
<DESCRIPTION>
<P>Although a single new abstract was identified which was eligible for inclusion in the review, the limited narrative information provided has not led to any change in the conclusions of this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-03-25 10:28:27 +0000" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="16" MONTH="2" YEAR="2012"/>
<DESCRIPTION>
<P>No new references have been added to the review at this update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-03-25 10:28:24 +0000" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="16" MONTH="2" YEAR="2012"/>
<DESCRIPTION>
<P>A search of the Group's Cystic Fibrosis Trials Register did not identify any references potentially eligible for inclusion in this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-02-16 10:08:12 +0000" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="15" MONTH="4" YEAR="2010"/>
<DESCRIPTION>
<P>A search of the Cystic Fibrosis Trials Register identified two studies potentially eligible for inclusion in the review. One of these has been included (<LINK REF="STD-Lubin-1979" TYPE="STUDY">Lubin 1979</LINK>) and the other has been excluded (<LINK REF="STD-Tsang-1994" TYPE="STUDY">Tsang 1994</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-04-15 14:13:54 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="13" MONTH="5" YEAR="2009"/>
<DESCRIPTION>
<P>No changes - republished to fix technical problem.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-05-13 15:16:50 +0100" MODIFIED_BY="Paolo Rosati">
<DATE DAY="16" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-05-13 15:16:50 +0100" MODIFIED_BY="Paolo Rosati">
<DATE DAY="13" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>A search of the Group's Cystic Fibrosis Trials Register did not identify any references potentially eligible for inclusion in this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-06-16 12:43:40 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="22" MONTH="8" YEAR="2007"/>
<DESCRIPTION>
<P>The plain language summary has been re-drafted in light of the current guidance from The Cochrane Collaboration.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-06-16 12:42:53 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="22" MONTH="8" YEAR="2007"/>
<DESCRIPTION>
<P>A search of the Group's Cystic Fibrosis Trial's Register did not identify any new references which were eligible for inclusion in this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-06-16 12:42:20 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="16" MONTH="8" YEAR="2006"/>
<DESCRIPTION>
<P>A search of the Group's Cystic Fibrosis Trial's Register did not identify any new references which were eligible for inclusion in this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-06-16 12:40:38 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="17" MONTH="8" YEAR="2005"/>
<DESCRIPTION>
<P>It was decided by the review authors to remove the data analysis that was previously included within the review. It was felt that this analysis was inappropriate and it would be of more benefit to the reader to report the individual trial results narratively under the relevant outcomes.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-06-16 12:40:19 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="17" MONTH="8" YEAR="2005"/>
<DESCRIPTION>
<P>Two trials have been included within the review (Durie 1980; Proesmans 2003).</P>
<P>Three trials have been added to the 'Excluded studies' section of the review (Ansaldi-Balocco 1988; Gow 1981; Stead 1988).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-06-16 12:39:17 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="24" MONTH="2" YEAR="2004"/>
<DESCRIPTION>
<P>A search found two new trials for inclusion in the review (Chung 2000; Francisco 2002). However, we were not able to include any new data. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2016-05-18 15:16:21 +0100" MODIFIED_BY="Nikki Jahnke">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2016-05-18 15:16:21 +0100" MODIFIED_BY="Nikki Jahnke">
<SOURCE MODIFIED="2016-05-18 15:16:21 +0100" MODIFIED_BY="Nikki Jahnke">
<NAME>National Institute for Health Research</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>This systematic review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Cystic Fibrosis and Genetic Disorders Group.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-07-25 11:56:53 +0100" MODIFIED_BY="Nikki Jahnke">
<SUMMARY MODIFIED="2016-07-21 15:04:24 +0100" MODIFIED_BY="Nikki Jahnke">
<TITLE>Drugs for reducing stomach acid for people with cystic fibrosis</TITLE>
<SUMMARY_BODY MODIFIED="2016-07-21 15:04:24 +0100" MODIFIED_BY="Nikki Jahnke">
<P>
<B>Review question</B>
</P>
<P>We reviewed the evidence for using drugs to reduce stomach acid in people with cystic fibrosis.</P>
<P>
<B>Background</B>
</P>
<P>Cystic fibrosis causes damage to the lungs and the pancreas. The pancreas produces enzymes which are needed for the body to digest and absorb food. If the pancreas is damaged this can affect how people can absorb food. It can also increase acidity in the stomach, which may lead to heartburn and peptic ulcers. There are drugs that can reduce the amount of acid in the stomach. Trials of these drugs have shown that they can improve problems in the stomach and digestive system and in the absorption of fat. This is an updated version of the review.</P>
<P>
<B>Search date</B>
</P>
<P>The evidence is current to: 12 May 2016.</P>
<P>
<B>Study characteristics</B>
</P>
<P>The review included at 17 trials with a total of 273 children and adults. Seven of the trials were limited to children and four trials enrolled only adults, while the remainder enrolled people of any age. All the trials were run in single centres and lasted from five days to six months.</P>
<P>Most trials compared an intervention to placebo (a dummy treatment with no active medication). Six trials compared proton pump inhibitors (drugs which reduce the amount of acid made in the stomach, e.g. omeprazole and esomeprazole) to placebo and seven trials compared a H2 receptor antagonist (a second group of medicines that reduce the amount of acid made in the stomach, e.g. ranitidine and cimetidine) to placebo. One of the trials had three arms and compared a proton pump inhibitor to both a H2 receptor agonist and a placebo. In the remaining five trials, one compared pancrelipase (a combination of three enzymes (lipase, protease, and amylase) normally produced by the pancreas) to a combination of pancrelipase and misoprostol (a drug which protects the lining of the gut from stomach acid); one compared misoprostol to placebo and one trial compared enprostil (similar drug to misoprostol) to ranitidine. Two trials used sodium bicarbonate - one compared to placebo and the second compared to calcium carbonate.</P>
<P>
<B>Key results</B>
</P>
<P>We were not able to combine the results from these trials due to their design. Individual trials reported some improvements in abdominal pain and fat absorption. However, the trials did not report improvements for other outcomes such as lung function, quality of life, or survival. The different drugs studied caused some adverse events; mainly diarrhoea (two people withdrew from one trial because of this) and bloating due to wind. As we could not combine the results from these trials, we were not able to reach firm conclusions about whether people with cystic fibrosis would benefit from taking these drugs. New long-term trials are needed to examine the benefits and possible adverse effects for people with cystic fibrosis taking drugs to reduce stomach acid.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>There were 14 trials which had a cross-over design (where people taking part are given first one treatment and then another treatment) and we did not have the appropriate information to analyse the results properly. Few of the included trials reported clearly on aspects of trial quality or gave enough information to allow us to judge whether any factors might cause a potential risk of bias to the results.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-05-18 15:19:29 +0100" MODIFIED_BY="Nikki Jahnke">
<ABS_BACKGROUND MODIFIED="2016-05-18 15:14:53 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Malabsorption of fat and protein contributes to poor nutritional status in people with cystic fibrosis. Impaired pancreatic function may also result in increased gastric acidity, leading in turn to heartburn, peptic ulcers and the impairment of oral pancreatic enzyme replacement therapy. The administration of gastric acid-reducing agents has been used as an adjunct to pancreatic enzyme therapy to improve absorption of fat and gastro-intestinal symptoms in people with cystic fibrosis. It is important to establish the evidence regarding potential benefits of drugs that reduce gastric acidity in people with cystic fibrosis. This is an update of a previously published review.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effect of drug therapies for reducing gastric acidity for: nutritional status; symptoms associated with increased gastric acidity; fat absorption; lung function; quality of life and survival; and to determine if any adverse effects are associated with their use.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-05-18 13:08:16 +0100" MODIFIED_BY="Nikki Jahnke">
<P>We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register which comprises references identified from comprehensive electronic database searches, handsearches of relevant journals, abstract books and conference proceedings.</P>
<P>Most recent search of the Group's Trials Register: 12 May 2016.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomised and quasi-randomised trials involving agents that reduce gastric acidity compared to placebo or a comparator treatment.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Both authors independently selected trials, assessed trial quality and extracted data. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-05-18 15:19:29 +0100" MODIFIED_BY="Nikki Jahnke">
<P>The searches identified 39 trials; 17 of these, with 273 participants, were suitable for inclusion, but the number of trials assessing each of the different agents was small. Seven trials were limited to children and four trials enrolled only adults. Meta-analysis was not performed, 14 trials were of a cross-over design and we did not have the appropriate information to conduct comprehensive meta-analyses. All the trials were run in single centres and duration ranged from five days to six months. The included trials were generally not reported adequately enough to allow judgements on risk of bias.</P>
<P>However, one trial found that drug therapies that reduce gastric acidity improved gastro-intestinal symptoms such as abdominal pain; seven trials reported significant improvement in measures of fat malabsorption; and two trials reported no significant improvement in nutritional status. Only one trial reported measures of respiratory function and one trial reported an adverse effect with prostaglandin E2 analogue misoprostol. No trials have been identified assessing the effectiveness of these agents in improving quality of life, the complications of increased gastric acidity, or survival.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-06-10 10:02:35 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Trials have shown limited evidence that agents that reduce gastric acidity are associated with improvement in gastro-intestinal symptoms and fat absorption. Currently, there is insufficient evidence to indicate whether there is an improvement in nutritional status, lung function, quality of life, or survival. Furthermore, due to the unclear risks of bias in the included trials, we are unable to make firm conclusions based on the evidence reported therein. We therefore recommend that large, multicentre, randomised controlled clinical trials are undertaken to evaluate these interventions.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-07-25 11:51:24 +0100" MODIFIED_BY="Nikki Jahnke">
<BACKGROUND MODIFIED="2016-05-18 15:15:25 +0100" MODIFIED_BY="Nikki Jahnke">
<P>
<BR/>
</P>
<CONDITION MODIFIED="2008-06-16 12:47:20 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Cystic fibrosis (CF) is an autosomal recessive inherited disease that is most common in Caucasian populations having an estimated incidence of 1 in 2500 live births (<LINK REF="REF-CF-Foundation-1994" TYPE="REFERENCE">CF Foundation 1994</LINK>). It affects the epithelial chloride channels. Defects cause reduced epithelial salt and water secretion, leading to viscous mucus in various organs such as the lungs and pancreas. As a result, exocrine pancreatic insufficiency occurs in the majority of people with CF causing maldigestion of fat and protein. Malabsorption of fat and protein lead to considerable energy losses in the stools and can contribute to poor nutritional status in people with CF (<LINK REF="REF-Murphy-1991" TYPE="REFERENCE">Murphy 1991</LINK>). Malnutrition affects growth, increases the severity of pulmonary disease, and ultimately plays an important role in the shortening of lifespan in people with CF (<LINK REF="REF-Kraemer-1978" TYPE="REFERENCE">Kraemer 1978</LINK>). Furthermore, nutritional status is also related to lung function and exercise performance in people with CF (<LINK REF="REF-Neijens-1985" TYPE="REFERENCE">Neijens 1985</LINK>).</P>
<P>Absorption in the small intestine may also be affected by reduced bicarbonate secretion in the small bowel and pancreas, contributing to a lower duodenal pH (<LINK REF="REF-Weber-1984" TYPE="REFERENCE">Weber 1984</LINK>). This may impair and irreversibly inactivate pancreatic enzymes, which in turn may lead to increased gastric acidity resulting in heartburn, epigastric pain and gastric or duodenal ulcers.</P>
</CONDITION>
<INTERVENTION MODIFIED="2008-06-16 12:48:32 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Oral pancreatic enzyme therapy to improve the nutritional status and decrease maldigestion due to pancreatic insufficiency in people with CF has been available for several decades. Despite adequate pancreatic replacement therapy, many people with CF continue to excrete large amounts of fat and protein in their stools, which may contribute to malnutrition and weight loss.</P>
</INTERVENTION>
<THEORY MODIFIED="2008-06-16 12:50:33 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Orally administered pancreatic enzymes may be inactivated by gastric acid in people with CF with pancreatic insufficiency leading to fat and protein malabsorption (<LINK REF="STD-Zentler_x002d_Munro-1985" TYPE="STUDY">Zentler-Munro 1985</LINK>). The decrease in pancreatic bicarbonate secretion associated with CF impairs the release of enteric-coated pancreatic enzymes and reduces their effectiveness (<LINK REF="REF-Regan-1979" TYPE="REFERENCE">Regan 1979</LINK>). Studies have suggested that drug therapy which reduces gastric acid may improve the effectiveness of pancreatic replacement therapy (<LINK REF="REF-DiMagno-2001" TYPE="REFERENCE">DiMagno 2001</LINK>). Agents to reduce gastric acidity should provide a duodenal environment more conducive to efficient enzyme function. In adults with pancreatic dysfunction secondary to chronic pancreatitis, H2 receptor antagonists or proton pumps that reduce gastric acidity improved fat malabsorption (<LINK REF="REF-Bruno-1994" TYPE="REFERENCE">Bruno 1994</LINK>). Proton pump inhibitors and H2 receptor antagonists do this directly by inhibiting acid production from parietal cells. Synthetic prostaglandins can also be used to reduce gastric acid secretion and stimulate bicarbonate secretion from the small bowel.</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-05-18 15:15:25 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Improvements in fat absorption and overall nutrition are important in the treatment of people with CF. The major goals in the treatment of people with CF are to improve the quality of life, achieve normal growth, improve respiratory status and increase life expectancy. It is therefore important to establish whether adjunct drug therapy to reduce gastric acidity in people with CF who are being treated with pancreatic enzymes is beneficial.</P>
<P>This version of the review is an update of previous versions (<LINK REF="REF-Ng-2003" TYPE="REFERENCE">Ng 2003</LINK>; <LINK REF="REF-Ng-2012" TYPE="REFERENCE">Ng 2012</LINK>; <LINK REF="REF-Ng-2014" TYPE="REFERENCE">Ng 2014</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-06-16 12:51:53 +0100" MODIFIED_BY="Nikki Jahnke">
<P>To test the hypotheses that in people with CF, agents that reduce gastric acidity:</P>
<OL>
<LI>improve nutritional status, as assessed by weight, height and other indices of growth;</LI>
<LI>improve symptoms associated with increased gastric acidity such as heartburn and epigastric pain;</LI>
<LI>improve lung function, quality of life and survival;</LI>
<LI>do not have unacceptable adverse effects.</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2016-05-18 13:08:33 +0100" MODIFIED_BY="Nikki Jahnke">
<SELECTION_CRITERIA MODIFIED="2010-04-15 14:15:36 +0100" MODIFIED_BY="Nikki Jahnke">
<CRIT_STUDIES>
<P>Randomised controlled trials (RCTs) or quasi-randomised controlled trials (published and unpublished).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-08-13 17:20:16 +0100" MODIFIED_BY="Tracey Remmington">
<P>Children and adults with defined CF, diagnosed clinically and by sweat or gene testing including all ages and all degrees of severity.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-06-16 12:52:07 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Agents that reduce gastric acidity compared to placebo or a comparator treatment. The major drug groups are:</P>
<OL>
<LI>proton pump inhibitors;</LI>
<LI>H2 receptor antagonists.</LI>
</OL>
<P>Other drug therapies such as prostaglandin E2 analogues and sodium bicarbonate which reduce gastric acidity will also be considered. All doses and routes of administration will be considered.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-04-15 14:15:36 +0100" MODIFIED_BY="Nikki Jahnke">
<P>
<BR/>
</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-06-16 12:52:37 +0100" MODIFIED_BY="Nikki Jahnke">
<OL>
<LI>Measures of nutritional status as assessed by weight, height and other indices of growth</LI>
<LI>Symptoms related to increased gastric acidity such as epigastric pain, heartburn</LI>
<LI>Complications of increased gastric acidity such as gastric or duodenal ulcers</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2010-04-15 14:15:36 +0100" MODIFIED_BY="Nikki Jahnke">
<OL>
<LI>Faecal fat, faecal nitrogen excretion and other measures of fat malabsorption</LI>
<LI>Measures of lung function</LI>
<LI>Measures of quality of life</LI>
<LI>Mortality</LI>
<LI>Any adverse effects reported</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-05-18 13:08:33 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Relevant trials were identified from the Group's Cystic Fibrosis Trials Register using the term: antacids.</P>
<P>The Cystic Fibrosis Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of <I>The Cochrane Library</I>), weekly searches of MEDLINE, a search of Embase to 1995 and the prospective handsearching of two journals - <I>Pediatric Pulmonology </I>and the<I> Journal of Cystic Fibrosis</I>. Unpublished work is identified by searching the abstract books of three major cystic fibrosis conferences: the International Cystic Fibrosis Conference; the European Cystic Fibrosis Conference and the North American Cystic Fibrosis Conference. For full details of all searching activities for the register, please see the relevant sections of the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/CF/frame.html">Cystic Fibrosis and Genetic Disorders Group Module</A>.</P>
<P>Date of the most recent search of the Group's Cystic Fibrosis Trials Register: 12 May 2016.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-05-28 14:44:04 +0100" MODIFIED_BY="Nikki Jahnke">
<STUDY_SELECTION MODIFIED="2008-06-16 12:56:18 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Two authors independently selected the trials to be included in the review. Disagreement did not arise on the suitability of any trials for inclusion in the review or their quality. However, if this should occur during future updates of this review, we will reach consensus by discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-04-15 14:16:53 +0100" MODIFIED_BY="Nikki Jahnke">
<P>The authors independently extracted data using standard data acquisition forms. Again, disagreement did not arise between the authors. We will resolve any future disagreements on any extracted data by discussion.</P>
<P>All drugs which reduce gastric acidity were regarded as the intervention to be compared to the placebo and not split into individual drug comparisons.</P>
<P>We planned to group outcome data into those measured at 1, 3, 6 and 12 months and annually thereafter. However, we were unable to group data into the time points we had originally planned and so report results narratively from the end of each trial. The duration of each trial is detailed in the table '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'. For future updates of this review, if outcome data are recorded at other time periods, then consideration will be given to examining these as well.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-07-03 10:02:02 +0100" MODIFIED_BY="Nikki Jahnke">
<P>In order to establish a risk of bias for each included study, each author assessed the methodological quality of each trial using criteria suggested by Jüni (<LINK REF="REF-J_x00fc_ni-2001" TYPE="REFERENCE">Jüni 2001</LINK>). In particular, authors examined details of the generation of allocation sequence, the concealment of treatment allocation schedule, whether the trial was blinded, whether intention-to-treat analyses were possible from available data and if the number lost to follow up or subsequently excluded from the trial was recorded. In future updates of the review, we will resolve any disagreements that occur by discussion.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2010-04-21 12:12:24 +0100" MODIFIED_BY="Nikki Jahnke">
<P>For future updates of the review, if appropriate data are available, the authors will use the following methods to analyse binary and continuous outcome measures. For binary outcome measures, the authors plan to calculate a pooled estimate of the treatment effect for each outcome across the studies, (the odds of an outcome among treatment allocated participants to corresponding odds among controls). For continuous outcomes, the authors will record either a mean change from baseline for each group or mean post-treatment or intervention values and standard deviation (SD) for each group. They will calculate a pooled estimate of treatment effect by calculating the mean difference where appropriate.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2008-08-13 17:21:58 +0100" MODIFIED_BY="Tracey Remmington">
<P>Ideally, when conducting a meta-analysis combining results from cross-over trials, the authors would have liked to use the methods that are recommended by Elbourne and Curtin (<LINK REF="REF-Curtin-2002" TYPE="REFERENCE">Curtin 2002</LINK>; <LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). However, due to restrictions on the data that were available from the papers the only method that the authors were able to use was to treat the cross-over trials as if they were parallel trials. When trials did not report data in such a way that a correct analysis could be performed, the results were described narratively within the text rather than combine the results using inappropriate techniques. The primary authors of the cross-over trials have been approached for further individual patient data and order of treatment, but no data have yet been made available.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2008-06-16 12:59:52 +0100" MODIFIED_BY="Nikki Jahnke">
<P>In order to allow an intention-to-treat analysis, the authors will seek data on the number of participants with each outcome event, by allocated treated group, irrespective of compliance and whether or not the participant was later thought to be ineligible or otherwise excluded from treatment or follow up.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-05-28 14:44:04 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Due to the lack of trials it was not possible to investigate heterogeneity between trial results using the standard Chi<SUP>2</SUP> test and I<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). For future updates of the review we will test for heterogeneity using the Chi<SUP>2</SUP> test and I<SUP>2</SUP> statistic. We will consider the ranges of I<SUP>2</SUP> to relate to the degree of heterogeneity as follows:</P>
<UL>
<LI>0% to 40%: might not be important;</LI>
<LI>30% to 60%: may represent moderate heterogeneity;</LI>
<LI>50% to 90%: may represent substantial heterogeneity;</LI>
<LI>75% to 100%: considerable heterogeneity.</LI>
</UL>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2008-07-07 12:23:38 +0100" MODIFIED_BY="Nikki Jahnke">
<P>We examined the publications for potential reporting biases but were not able to compare the original trial protocols with the final publications. We were therefore unable to identify any potential reporting biases.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-06-16 13:00:52 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Where between trial variability is not statistically significant we will carry out a fixed effect analysis and if the between trial heterogeneity is statistically significant we will perform a random effects analysis.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2008-06-16 13:01:07 +0100" MODIFIED_BY="Nikki Jahnke">
<P>If there is significant heterogeneity between the trials, the authors plan to perform a subgroup analysis investigating different classes of drugs.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2008-06-16 13:01:17 +0100" MODIFIED_BY="Nikki Jahnke">
<P>The authors also plan to perform a sensitivity analysis based on methodological quality of the trials including and excluding quasi-randomised trials, when it is appropriate to do so.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-07-25 11:51:24 +0100" MODIFIED_BY="Nikki Jahnke">
<STUDY_DESCRIPTION MODIFIED="2016-07-25 11:51:24 +0100" MODIFIED_BY="Nikki Jahnke">
<SEARCH_RESULTS MODIFIED="2014-05-28 14:45:25 +0100" MODIFIED_BY="Nikki Jahnke">
<P>A total of 39 trials were identified from the searches; 17 trials were included and 22 trials were excluded.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-07-25 11:51:24 +0100" MODIFIED_BY="Nikki Jahnke">
<P>There was a large variation between the trials identified in terms of design, intervention, duration of treatment and outcome measures. <I>See</I> <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table for full details.</P>
<P>We included 17 trials in this review. All of the included trials were published, but four of them were published only as abstracts in conference proceedings (<LINK REF="STD-Bowler-1993" TYPE="STUDY">Bowler 1993</LINK>; <LINK REF="STD-Chung-2000" TYPE="STUDY">Chung 2000</LINK>; <LINK REF="STD-Lubin-1979" TYPE="STUDY">Lubin 1979</LINK>; <LINK REF="STD-Weber-1981" TYPE="STUDY">Weber 1981</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Trial design</HEADING>
<P>Fourteen trials were cross-over in design (<LINK REF="STD-Bowler-1993" TYPE="STUDY">Bowler 1993</LINK>; <LINK REF="STD-Boyle-1980" TYPE="STUDY">Boyle 1980</LINK>; <LINK REF="STD-Carroccio-1992" TYPE="STUDY">Carroccio 1992</LINK>; <LINK REF="STD-Chalmers-1985" TYPE="STUDY">Chalmers 1985</LINK>; <LINK REF="STD-Chung-2000" TYPE="STUDY">Chung 2000</LINK>; <LINK REF="STD-Durie-1980" TYPE="STUDY">Durie 1980</LINK>; <LINK REF="STD-Francisco-2002" TYPE="STUDY">Francisco 2002</LINK>; <LINK REF="STD-Heijerman-1990" TYPE="STUDY">Heijerman 1990</LINK>; <LINK REF="STD-Heijerman-1991" TYPE="STUDY">Heijerman 1991</LINK>; <LINK REF="STD-Heijerman-1993" TYPE="STUDY">Heijerman 1993</LINK>; <LINK REF="STD-Proesmans-2003" TYPE="STUDY">Proesmans 2003</LINK>; <LINK REF="STD-Robinson-1988" TYPE="STUDY">Robinson 1988</LINK>; <LINK REF="STD-Robinson-1990" TYPE="STUDY">Robinson 1990</LINK>; <LINK REF="STD-Weber-1981" TYPE="STUDY">Weber 1981</LINK>). Three trials were of a parallel design (<LINK REF="STD-Lubin-1979" TYPE="STUDY">Lubin 1979</LINK>; <LINK REF="STD-Schoni-1984" TYPE="STUDY">Schoni 1984</LINK>; <LINK REF="STD-DiMango-2014" TYPE="STUDY">DiMango 2014</LINK>).</P>
<P>Trial duration ranged from 12 days (three days in each of the four treatment arms in this cross-over trial) (<LINK REF="STD-Francisco-2002" TYPE="STUDY">Francisco 2002</LINK>) to one year (again in cross-over trials with treatment periods of six months in each arm) (<LINK REF="STD-Carroccio-1992" TYPE="STUDY">Carroccio 1992</LINK>; <LINK REF="STD-Chalmers-1985" TYPE="STUDY">Chalmers 1985</LINK>); duration was not stated in one trial (<LINK REF="STD-Lubin-1979" TYPE="STUDY">Lubin 1979</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Participants</HEADING>
<P>The included trials reported results from a total of 273 participants. Sample size varied from five (<LINK REF="STD-Chung-2000" TYPE="STUDY">Chung 2000</LINK>) to 38 participants (<LINK REF="STD-Schoni-1984" TYPE="STUDY">Schoni 1984</LINK>), with participants' ages ranging from six months (<LINK REF="STD-Robinson-1990" TYPE="STUDY">Robinson 1990</LINK>) to 42 years (<LINK REF="STD-Heijerman-1993" TYPE="STUDY">Heijerman 1993</LINK>). Seven trials were limited to children (<LINK REF="STD-Bowler-1993" TYPE="STUDY">Bowler 1993</LINK>; <LINK REF="STD-Chung-2000" TYPE="STUDY">Chung 2000</LINK>; <LINK REF="STD-Lubin-1979" TYPE="STUDY">Lubin 1979</LINK>; <LINK REF="STD-Robinson-1988" TYPE="STUDY">Robinson 1988</LINK>; <LINK REF="STD-Robinson-1990" TYPE="STUDY">Robinson 1990</LINK>; <LINK REF="STD-Schoni-1984" TYPE="STUDY">Schoni 1984</LINK>; <LINK REF="STD-Weber-1981" TYPE="STUDY">Weber 1981</LINK>); and three trials enrolled only adults (<LINK REF="STD-Heijerman-1990" TYPE="STUDY">Heijerman 1990</LINK>; <LINK REF="STD-Heijerman-1991" TYPE="STUDY">Heijerman 1991</LINK>; <LINK REF="STD-Heijerman-1993" TYPE="STUDY">Heijerman 1993</LINK>).</P>
<P>In one trial participants were grouped according to acetylation phenotype (slow or fast) and matched according to their age before the trial (<LINK REF="STD-Schoni-1984" TYPE="STUDY">Schoni 1984</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Interventions</HEADING>
<P>Most trials compared an intervention to placebo.</P>
<P>Six trials compared proton pump inhibitors with placebo (<LINK REF="STD-Chung-2000" TYPE="STUDY">Chung 2000</LINK>; <LINK REF="STD-DiMango-2014" TYPE="STUDY">DiMango 2014</LINK>; <LINK REF="STD-Francisco-2002" TYPE="STUDY">Francisco 2002</LINK>; <LINK REF="STD-Heijerman-1991" TYPE="STUDY">Heijerman 1991</LINK>; <LINK REF="STD-Heijerman-1993" TYPE="STUDY">Heijerman 1993</LINK>; <LINK REF="STD-Proesmans-2003" TYPE="STUDY">Proesmans 2003</LINK>). Participants in two trials were randomised to receive either omeprazole or placebo; but in the Francisco trial this was only the case for the adult participants (<LINK REF="STD-Chung-2000" TYPE="STUDY">Chung 2000</LINK>; <LINK REF="STD-Francisco-2002" TYPE="STUDY">Francisco 2002</LINK>). In a third trial, participants received either esomeprazole 40 mg or placebo twice daily (<LINK REF="STD-DiMango-2014" TYPE="STUDY">DiMango 2014</LINK>). In the later Heijerman trial, participants were given either pancrealipase plus omeprazole or pancrealipase and placebo (<LINK REF="STD-Heijerman-1993" TYPE="STUDY">Heijerman 1993</LINK>). In a further trial, one group of participants received omeprazole and the other treatment group received no omeprazole (<LINK REF="STD-Proesmans-2003" TYPE="STUDY">Proesmans 2003</LINK>). In a cross-over trial consisting of four comparative treatment periods participants received: firstly a high dose of pancreatic enzyme, pancrelipase (Pancrease®) (four capsules, three times daily) in conjunction with a proton pump inhibitor, omeprazole; secondly, high-dose pancrelipase in conjunction with placebo; thirdly, low-dose pancrelipase (two capsules, three times daily) in conjunction with omeprazole; and fourthly, low-dose pancrelipase in conjunction with placebo (<LINK REF="STD-Heijerman-1991" TYPE="STUDY">Heijerman 1991</LINK>).</P>
<P>Seven trials compared a H2 receptor antagonist with placebo (<LINK REF="STD-Bowler-1993" TYPE="STUDY">Bowler 1993</LINK>; <LINK REF="STD-Boyle-1980" TYPE="STUDY">Boyle 1980</LINK>; <LINK REF="STD-Carroccio-1992" TYPE="STUDY">Carroccio 1992</LINK>; <LINK REF="STD-Chalmers-1985" TYPE="STUDY">Chalmers 1985</LINK>; <LINK REF="STD-Durie-1980" TYPE="STUDY">Durie 1980</LINK>; <LINK REF="STD-Francisco-2002" TYPE="STUDY">Francisco 2002</LINK>; <LINK REF="STD-Schoni-1984" TYPE="STUDY">Schoni 1984</LINK>). In one trial, participants received one of three treatments in a randomly-assigned sequence: high-dose pancreatic enzyme (Creon®) with the H2 receptor antagonist, ranitidine; high-dose pancreatic enzyme with placebo; or lower-dose pancreatic enzyme with placebo (<LINK REF="STD-Bowler-1993" TYPE="STUDY">Bowler 1993</LINK>). In another trial, participants received pancreatic enzyme alone (Viokase®) or pancreatic enzyme (Viokase®) and the H2 receptor antagonist, cimetidine (<LINK REF="STD-Boyle-1980" TYPE="STUDY">Boyle 1980</LINK>). Carroccio investigated famotidine or placebo given in addition to normal enzyme therapy (<LINK REF="STD-Carroccio-1992" TYPE="STUDY">Carroccio 1992</LINK>). In the Chalmers trial, participants received either cimetidine or placebo in addition to normal enzyme therapy (<LINK REF="STD-Chalmers-1985" TYPE="STUDY">Chalmers 1985</LINK>). The trial by Durie contained four treatment groups, who received each treatment in a random order; the four interventions that were used were: pancrelipase; sodium bicarbonate; cimetidine; and a combination of sodium bicarbonate and cimetidine (<LINK REF="STD-Durie-1980" TYPE="STUDY">Durie 1980</LINK>). As part of a trial, already mentioned in the previous paragraph, participants who were pancreatic insufficient were randomised to receive high-dose or low-dose ranitidine compared with placebo in a cross-over trial (<LINK REF="STD-Francisco-2002" TYPE="STUDY">Francisco 2002</LINK>). In the trial by Schoni, the effectiveness of cimetidine compared to placebo was evaluated (<LINK REF="STD-Schoni-1984" TYPE="STUDY">Schoni 1984</LINK>).</P>
<P>One trial compared the normal dose pancrelipase and prostaglandin E2 analogue misoprostol (100 &#956;g every six hours) with the normal dose pancrease alone (<LINK REF="STD-Robinson-1988" TYPE="STUDY">Robinson 1988</LINK>), a further trial compared the prostaglandin E2 analogue misoprostol with placebo (<LINK REF="STD-Robinson-1990" TYPE="STUDY">Robinson 1990</LINK>). One trial compared sodium bicarbonate with placebo (<LINK REF="STD-Weber-1981" TYPE="STUDY">Weber 1981</LINK>).</P>
<P>A further trial compared two active treatment arms, the H2 receptor antagonist (ranitidine) with prostaglandin E2 analogue (enprostil) (<LINK REF="STD-Heijerman-1990" TYPE="STUDY">Heijerman 1990</LINK>). One trial compared sodium bicarbonate with calcium carbonate (<LINK REF="STD-Lubin-1979" TYPE="STUDY">Lubin 1979</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcomes</HEADING>
<P>Data for measuring fat malabsorption were presented in different ways such as percentage fat malabsorption (three-day fat excretion/three times mean daily fat intake), faecal fat excretion (percentage daily fat intake), percentage fat absorption, faecal weight (g/24 h), and faecal fat (g/24 h). One trial used a gastro-intestinal symptom score which incorporated a subjective measure for the frequency and severity of symptoms (<LINK REF="STD-Heijerman-1990" TYPE="STUDY">Heijerman 1990</LINK>). Gastro-intestinal complaints were each scored: none = 0; little = 1; moderate = 2; severe = 3; and very severe = 4. These scores were then combined to give an overall complaints score which was analysed as a continuous variable. Another trial relied on participants reporting relief from chronic abdominal pain (<LINK REF="STD-Robinson-1988" TYPE="STUDY">Robinson 1988</LINK>).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-05-28 14:47:58 +0100" MODIFIED_BY="Nikki Jahnke">
<P>In total, 22 trials were excluded for a variety of reasons. Six trials were not RCTs (<LINK REF="STD-Cameron-1982" TYPE="STUDY">Cameron 1982</LINK>; <LINK REF="STD-Cox-1981" TYPE="STUDY">Cox 1981</LINK>; <LINK REF="STD-Dudley-1981" TYPE="STUDY">Dudley 1981</LINK>; <LINK REF="STD-Lloyd_x002d_Still-1992" TYPE="STUDY">Lloyd-Still 1992</LINK>; <LINK REF="STD-Miller-1985" TYPE="STUDY">Miller 1985</LINK>; <LINK REF="STD-Miller-1986" TYPE="STUDY">Miller 1986</LINK>); seven trials examined agents which are not used to reduce gastric acidity (<LINK REF="STD-Ansaldi_x002d_Balocco-1988" TYPE="STUDY">Ansaldi-Balocco 1988</LINK>; <LINK REF="STD-Geus-1999" TYPE="STUDY">Geus 1999</LINK>; <LINK REF="STD-Hoffman-1987" TYPE="STUDY">Hoffman 1987</LINK>; <LINK REF="STD-Kerr-1982" TYPE="STUDY">Kerr 1982</LINK>; <LINK REF="STD-Mitchell-1981" TYPE="STUDY">Mitchell 1981</LINK>; <LINK REF="STD-Stead-1988" TYPE="STUDY">Stead 1988</LINK>; <LINK REF="STD-Tsang-1994" TYPE="STUDY">Tsang 1994</LINK>); five trials compared cisapride (a pro-kinetic agent) with a drug for reducing gastric acidity (<LINK REF="STD-Cucchiara-1996" TYPE="STUDY">Cucchiara 1996</LINK>; <LINK REF="STD-Koletzo-1989" TYPE="STUDY">Koletzo 1989</LINK>; <LINK REF="STD-Prinsen-1985" TYPE="STUDY">Prinsen 1985</LINK>; <LINK REF="STD-Santamaria-1989" TYPE="STUDY">Santamaria 1989</LINK>; <LINK REF="STD-Smith-1988" TYPE="STUDY">Smith 1988</LINK>); one trial compared the accuracy of fat balance trials at home versus at a clinic (<LINK REF="STD-Francisco-1996" TYPE="STUDY">Francisco 1996</LINK>); one trial contained four treatment periods, three of which were not relevant to the review, so no comparison could be made (<LINK REF="STD-Gow-1981" TYPE="STUDY">Gow 1981</LINK>); one trial compared the pharmacokinetics of oral versus intravenous famotidine (<LINK REF="STD-Maish-1998" TYPE="STUDY">Maish 1998</LINK>); and one trial assessed lipase, bile acid and trypsin concentration (<LINK REF="STD-Zentler_x002d_Munro-1985" TYPE="STUDY">Zentler-Munro 1985</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-05-18 13:05:19 +0100" MODIFIED_BY="Nikki Jahnke">
<P>In order to assess the risk of bias in the included trials, the authors assessed the methodological quality of the included trials using criteria suggested by Jüni for the following dimensions: concealment of allocation; generation of the randomisation sequence; intention-to-treat; and level of blinding reported (<LINK REF="REF-J_x00fc_ni-2001" TYPE="REFERENCE">Jüni 2001</LINK>). The dimensions, concealment of allocation, generation of the randomisation sequence and intention-to-treat were categorised as adequate, unclear or inadequate which related to a low, unclear or high risk of bias respectively; RCTs were categorised according to whether double blinding had been reported or not. There is a decreasing risk of bias to the results when more people are blinded to an intervention.</P>
<ALLOCATION MODIFIED="2016-05-18 13:05:19 +0100" MODIFIED_BY="Nikki Jahnke">
<P>All trials stated that allocation was randomised, but no trials described the method of randomisation used. We therefore judged the risk of bias due to the generation of the randomisation sequence as unclear in all trials.</P>
<P>Concealment of allocation was adequate in only one trial in which the randomisation procedure was carried out at the pharmacy in the hospital (<LINK REF="STD-Robinson-1990" TYPE="STUDY">Robinson 1990</LINK>). The trial organisers were unaware of this sequence until the completion of the trial. We judged this trial to have a low risk of bias. However, concealment of allocation, and also the risk of bias, was unclear in the remaining 16 trials (<LINK REF="STD-Bowler-1993" TYPE="STUDY">Bowler 1993</LINK>; <LINK REF="STD-Boyle-1980" TYPE="STUDY">Boyle 1980</LINK>; <LINK REF="STD-Carroccio-1992" TYPE="STUDY">Carroccio 1992</LINK>; <LINK REF="STD-Chalmers-1985" TYPE="STUDY">Chalmers 1985</LINK>; <LINK REF="STD-Chung-2000" TYPE="STUDY">Chung 2000</LINK>; <LINK REF="STD-DiMango-2014" TYPE="STUDY">DiMango 2014</LINK>; <LINK REF="STD-Durie-1980" TYPE="STUDY">Durie 1980</LINK>; <LINK REF="STD-Francisco-2002" TYPE="STUDY">Francisco 2002</LINK>; <LINK REF="STD-Heijerman-1990" TYPE="STUDY">Heijerman 1990</LINK>; <LINK REF="STD-Heijerman-1991" TYPE="STUDY">Heijerman 1991</LINK>; <LINK REF="STD-Heijerman-1993" TYPE="STUDY">Heijerman 1993</LINK>; <LINK REF="STD-Lubin-1979" TYPE="STUDY">Lubin 1979</LINK>; <LINK REF="STD-Proesmans-2003" TYPE="STUDY">Proesmans 2003</LINK>; <LINK REF="STD-Robinson-1988" TYPE="STUDY">Robinson 1988</LINK>; <LINK REF="STD-Schoni-1984" TYPE="STUDY">Schoni 1984</LINK>; <LINK REF="STD-Weber-1981" TYPE="STUDY">Weber 1981</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2016-05-18 13:05:19 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Double-blinding was reported in 13 of the 17 included trials; however, two trials did not report blinding of investigators (<LINK REF="STD-Boyle-1980" TYPE="STUDY">Boyle 1980</LINK>; <LINK REF="STD-Lubin-1979" TYPE="STUDY">Lubin 1979</LINK>). In one trial, Robinson reported that parents of 5 out of 15 children in the treatment group were able to correctly identify the period in which misoprostol was administered by improvements in symptoms such as abdominal pain and offensive bulky bowel motions (<LINK REF="STD-Robinson-1990" TYPE="STUDY">Robinson 1990</LINK>). In two trials the level of blinding was not discussed (<LINK REF="STD-DiMango-2014" TYPE="STUDY">DiMango 2014</LINK>; <LINK REF="STD-Durie-1980" TYPE="STUDY">Durie 1980</LINK>) and a further trial was not blinded (<LINK REF="STD-Proesmans-2003" TYPE="STUDY">Proesmans 2003</LINK>).</P>
<P>We considered the risk of bias from blinding to decrease if more people were blinded to the intervention and the risk of bias to be unclear if this aspect of trial quality was not discussed.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2016-05-18 13:05:19 +0100" MODIFIED_BY="Nikki Jahnke">
<P>No trials explicitly stated that an intention-to-treat analysis was performed. Neither did any trial state that any participants deviated from the randomised group to which they were assigned. In six trials there were no participant withdrawals reported, but it was not explicitly stated that no participants withdrew (<LINK REF="STD-DiMango-2014" TYPE="STUDY">DiMango 2014</LINK>; <LINK REF="STD-Heijerman-1991" TYPE="STUDY">Heijerman 1991</LINK>; <LINK REF="STD-Heijerman-1993" TYPE="STUDY">Heijerman 1993</LINK>; <LINK REF="STD-Lubin-1979" TYPE="STUDY">Lubin 1979</LINK>; <LINK REF="STD-Schoni-1984" TYPE="STUDY">Schoni 1984</LINK>; <LINK REF="STD-Weber-1981" TYPE="STUDY">Weber 1981</LINK>). Therefore we judged the risk of bias to be unclear in these four trials. The remaining 11 included trials experienced participant withdrawals (<LINK REF="STD-Bowler-1993" TYPE="STUDY">Bowler 1993</LINK>; <LINK REF="STD-Boyle-1980" TYPE="STUDY">Boyle 1980</LINK>; <LINK REF="STD-Carroccio-1992" TYPE="STUDY">Carroccio 1992</LINK>; <LINK REF="STD-Chalmers-1985" TYPE="STUDY">Chalmers 1985</LINK>; <LINK REF="STD-Chung-2000" TYPE="STUDY">Chung 2000</LINK>; <LINK REF="STD-Durie-1980" TYPE="STUDY">Durie 1980</LINK>; <LINK REF="STD-Francisco-2002" TYPE="STUDY">Francisco 2002</LINK>; <LINK REF="STD-Heijerman-1990" TYPE="STUDY">Heijerman 1990</LINK>; <LINK REF="STD-Proesmans-2003" TYPE="STUDY">Proesmans 2003</LINK>; <LINK REF="STD-Robinson-1988" TYPE="STUDY">Robinson 1988</LINK>; <LINK REF="STD-Robinson-1990" TYPE="STUDY">Robinson 1990</LINK>). In 10 trials there were a low number of participant withdrawals and these were described, but in the remaining trial there was a discrepancy between the number of participants entering and completing the trial which was not addressed (<LINK REF="STD-Bowler-1993" TYPE="STUDY">Bowler 1993</LINK>). We judged the risk of bias to be low in the 10 trials which accounted for participant withdrawals, but high in the trial which did not give any reason for the missing data from one participant.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2008-07-07 11:59:47 +0100" MODIFIED_BY="Nikki Jahnke">
<P>We were unable to identify any selective reporting in the included trials, but did not have any access to the original trial protocols to definitely confirm this; we therefore conclude that there is an unclear risk of bias due to selective reporting. </P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2008-07-07 12:06:37 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Durie states that the participants were selected from a restricted geographical area in proximity to the hospital on the basis of an assessment by clinical personnel of their ability to perform a clinical study accurately at home (<LINK REF="STD-Durie-1980" TYPE="STUDY">Durie 1980</LINK>). This may present a potential risk of bias due to pre-selection of participants by clinic personnel.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-05-18 13:05:19 +0100" MODIFIED_BY="Nikki Jahnke">
<P>We were unable to group data into the time points we had originally planned and so report results narratively from the end of each trial. The duration of each trial is detailed in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">Drugs for reducing gastric acidity versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1. Measures of nutritional status</HEADING>
<P>Data on growth indices and nutritional status were available from two trials comparing an H2 receptor antagonist with a placebo (<LINK REF="STD-Chalmers-1985" TYPE="STUDY">Chalmers 1985</LINK>; <LINK REF="STD-Schoni-1984" TYPE="STUDY">Schoni 1984</LINK>). We were unable to pool data from the trial by Chalmers because there were insufficient data to calculate the SD (<LINK REF="STD-Chalmers-1985" TYPE="STUDY">Chalmers 1985</LINK>). Both trials reported that there were no significant improvements in height, weight and skinfold thickness between the treatment and the control group (<LINK REF="STD-Chalmers-1985" TYPE="STUDY">Chalmers 1985</LINK>; <LINK REF="STD-Schoni-1984" TYPE="STUDY">Schoni 1984</LINK>). Body mass index and z scores for weight and height were not reported in either trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Measures of gastro-intestinal symptoms</HEADING>
<P>These measures were recorded in nine trials (<LINK REF="STD-Bowler-1993" TYPE="STUDY">Bowler 1993</LINK>; <LINK REF="STD-Boyle-1980" TYPE="STUDY">Boyle 1980</LINK>; <LINK REF="STD-Carroccio-1992" TYPE="STUDY">Carroccio 1992</LINK>; <LINK REF="STD-Chalmers-1985" TYPE="STUDY">Chalmers 1985</LINK>; <LINK REF="STD-Heijerman-1991" TYPE="STUDY">Heijerman 1991</LINK>; <LINK REF="STD-Heijerman-1993" TYPE="STUDY">Heijerman 1993</LINK>; <LINK REF="STD-Robinson-1988" TYPE="STUDY">Robinson 1988</LINK>; <LINK REF="STD-Robinson-1990" TYPE="STUDY">Robinson 1990</LINK>; <LINK REF="STD-Weber-1981" TYPE="STUDY">Weber 1981</LINK>), but not reported in eight of the trials.</P>
<P>In the 1988 trial, Robinson looked at relief from chronic abdominal pain in the treatment group compared with the control group (<LINK REF="STD-Robinson-1988" TYPE="STUDY">Robinson 1988</LINK>). There were six participants who reported relief in the treatment group and none in the control group. The symptoms returned in five of the six participants after misoprostol was stopped at the end of the trial period.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Complications of increased gastric acidity such as gastric or duodenal ulcers</HEADING>
<P>These outcomes were either not reported or the data were not available in any of the trial reports.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1. Measures of fat malabsorption</HEADING>
<P>In the 1993 trial, Heijerman reported the results for faecal fat excretion and found that there was no statistically significant difference between the treatment and control groups (<LINK REF="STD-Heijerman-1993" TYPE="STUDY">Heijerman 1993</LINK>). However, previously in his 1991 trial, Heijerman found significantly lower faecal fat excretion (percentage of daily fat intake) (P &lt; 0.01) when omeprazole was combined with higher dose pancrelipase enzymes (four capsules, three times daily) (<LINK REF="STD-Heijerman-1991" TYPE="STUDY">Heijerman 1991</LINK>). Improvement in faecal fat excretion when omeprazole was added to lower dose pancrelipase (two capsules, three times daily) occurred in seven of the nine adults studied, but was not significant for the whole group. Proesmans reported that the effect of omeprazole on daily faecal fat loss (g/day) was statistically significant (P &lt; 0.01) (<LINK REF="STD-Proesmans-2003" TYPE="STUDY">Proesmans 2003</LINK>).</P>
<P>The 1988 Robinson trial found a significant reduction of fat malabsorption in the treatment group (P &lt; 0.02), only the P value was available from this trial (<LINK REF="STD-Robinson-1988" TYPE="STUDY">Robinson 1988</LINK>). The later Robinson trial reported that there was a significant reduction in fat malabsorption while taking misoprostol (P &lt; 0.01) with no change in daily fat intake (<LINK REF="STD-Robinson-1990" TYPE="STUDY">Robinson 1990</LINK>).</P>
<P>Boyle showed that cimetidine significantly reduced the mean stool weight (P &lt; 0.005) (<LINK REF="STD-Boyle-1980" TYPE="STUDY">Boyle 1980</LINK>). Carroccio also showed that famotidine significantly reduced faecal weight (P &lt; 0.0001) (<LINK REF="STD-Carroccio-1992" TYPE="STUDY">Carroccio 1992</LINK>). Weber showed no significant difference between sodium bicarbonate and placebo (<LINK REF="STD-Weber-1981" TYPE="STUDY">Weber 1981</LINK>).</P>
<P>No significant improvement was found for faecal fat (g/day) between treatment and placebo groups in the Weber trial (<LINK REF="STD-Weber-1981" TYPE="STUDY">Weber 1981</LINK>). Chalmers reported a significant reduction in faecal fat in the treatment group (P &lt; 0.05), but no statistical difference was found for mean faecal wet weight (g/day) (<LINK REF="STD-Chalmers-1985" TYPE="STUDY">Chalmers 1985</LINK>). A trial by Bowler showed no significant difference in faecal fat or faecal weight when comparing both high lipase enzyme and with the addition of ranitidine to control (<LINK REF="STD-Bowler-1993" TYPE="STUDY">Bowler 1993</LINK>). A trial by Boyle comparing cimetidine with placebo reported a significant difference in faecal fat (g/day) (P &lt; 0.05) (<LINK REF="STD-Boyle-1980" TYPE="STUDY">Boyle 1980</LINK>). A trial by Francisco reported no significant difference in fat absorption between high-dose or low-dose ranitidine compared with placebo groups in children or between omeprazole and placebo groups in the adult participants (<LINK REF="STD-Francisco-2002" TYPE="STUDY">Francisco 2002</LINK>). Chung also reported no significant difference in malabsorption between high-dose omeprazole or placebo groups (<LINK REF="STD-Chung-2000" TYPE="STUDY">Chung 2000</LINK>).</P>
<P>Boyle reported a significant improvement in fat absorption in the treatment group compared with the placebo group (P &lt; 0.05) (<LINK REF="STD-Boyle-1980" TYPE="STUDY">Boyle 1980</LINK>).</P>
<P>Durie calculated faecal fat and nitrogen as g/24 h and percentage of intake (<LINK REF="STD-Durie-1980" TYPE="STUDY">Durie 1980</LINK>). Cimetidine and sodium bicarbonate, both individually and in combination with each other, significantly improved fat and nitrogen excretion. However, the results from the combination of cimetidine and sodium bicarbonate were no better than those from cimetidine and sodium bicarbonate individually. Durie suggested that this meant that response to the single drug regimens were maximal (<LINK REF="STD-Durie-1980" TYPE="STUDY">Durie 1980</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Measures of lung function</HEADING>
<P>Data for forced expiratory volume in one second (FEV<SUB>1</SUB>), forced vital capacity (FVC), forced expiratory flow rate (FEF<SUB>25-75%</SUB>) were not available in any of the trials. </P>
<P>Both the Chalmers and the DiMango trials reported objective measures of lung function narratively (<LINK REF="STD-Chalmers-1985" TYPE="STUDY">Chalmers 1985</LINK>; <LINK REF="STD-DiMango-2014" TYPE="STUDY">DiMango 2014</LINK>). Chalmers found no significant difference in mean change in peak flow or Crispin-Norman score after six months of treatment (<LINK REF="STD-Chalmers-1985" TYPE="STUDY">Chalmers 1985</LINK>) and the DiMango abstract reported that neither the esomeprazole group or the placebo group demonstrated a significant change in FEV<SUB>1</SUB> after 24 weeks (<LINK REF="STD-DiMango-2014" TYPE="STUDY">DiMango 2014</LINK>). One trial measured lung function (<LINK REF="STD-Schoni-1984" TYPE="STUDY">Schoni 1984</LINK>) and another trial measured Crispin-Norman scores (<LINK REF="STD-Carroccio-1992" TYPE="STUDY">Carroccio 1992</LINK>), but no data were reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Measures of quality of life</HEADING>
<P>Only the Di Mango abstract, mentioned quality of life and reported that neither the esomeprazole group or the placebo group demonstrated a significant change in CFQ-R (<LINK REF="STD-DiMango-2014" TYPE="STUDY">DiMango 2014</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Mortality</HEADING>
<P>These outcomes were either not reported or the data were not available in any of the trial reports.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. Adverse effects</HEADING>
<P>The trial by Robinson reported diarrhoea as an adverse effect experienced by participants on the prostaglandin E2 analogue, misoprostol (<LINK REF="STD-Robinson-1990" TYPE="STUDY">Robinson 1990</LINK>). Two participants had to be withdrawn from the trial because of diarrhoea that did not subside after five days.</P>
<P>Durie reported that two participants complained of gaseous abdominal distension while taking sodium bicarbonate and one participant was forced to withdraw from the trial because of possible neurological complications due to cimetidine (<LINK REF="STD-Durie-1980" TYPE="STUDY">Durie 1980</LINK>).</P>
<P>DiMango reported that participants receiving esomeprazole experienced a shorter time to first exacerbation compared with placebo, but the difference was not statistically significant. Further, five of eight participants receiving esomeprazole compared with two of six participants receiving placebo developed a pulmonary exacerbation during the six-month follow up (P = 0.11) (<LINK REF="STD-DiMango-2014" TYPE="STUDY">DiMango 2014</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">H2 receptor antagonist ranitidine versus prostaglandin E2 analogue enprostil</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1. Measures of nutritional status</HEADING>
<P>These outcomes were either not reported or the data were not available in the trial report (<LINK REF="STD-Heijerman-1990" TYPE="STUDY">Heijerman 1990</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Measures of gastro-intestinal symptoms</HEADING>
<P>The included trial reported a gastro-intestinal complaints score measured at 14 days comparing H2 receptor antagonist ranitidine with prostaglandin E2 analogue enprostil (<LINK REF="STD-Heijerman-1990" TYPE="STUDY">Heijerman 1990</LINK>). In the original paper, participants receiving the H2 receptor antagonist ranitidine were reported to have significantly less gastro-intestinal complaints compared with participants receiving prostaglandin E2 analogue enprostil (P &lt; 0.05).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Complications of increased gastric acidity such as gastric or duodenal ulcers</HEADING>
<P>These outcomes were either not reported or the data were not available in the trial report (<LINK REF="STD-Heijerman-1990" TYPE="STUDY">Heijerman 1990</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1. Measures of fat malabsorption</HEADING>
<P>The included trial found no significant difference in mean percentage faecal fat excretion (<LINK REF="STD-Heijerman-1990" TYPE="STUDY">Heijerman 1990</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Measures of lung function</HEADING>
<P>These outcomes were either not reported or the data were not available in the trial report (<LINK REF="STD-Heijerman-1990" TYPE="STUDY">Heijerman 1990</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Measures of quality of life</HEADING>
<P>These outcomes were either not reported or the data were not available in the trial report (<LINK REF="STD-Heijerman-1990" TYPE="STUDY">Heijerman 1990</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Mortality</HEADING>
<P>These outcomes were either not reported or the data were not available in the trial report (<LINK REF="STD-Heijerman-1990" TYPE="STUDY">Heijerman 1990</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. Adverse effects</HEADING>
<P>The included trial reported diarrhoea and abdominal discomfort as adverse effects in participants on the prostaglandin E2 analogue, enprostil treatment (<LINK REF="STD-Heijerman-1990" TYPE="STUDY">Heijerman 1990</LINK>). One person in the enprostil group withdrew during the treatment period because of these effects.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sodium bicarbonate versus calcium carbonate</HEADING>
<P>Only one trial compared sodium bicarbonate to calcium carbonate (<LINK REF="STD-Lubin-1979" TYPE="STUDY">Lubin 1979</LINK>). This trial only reported on one outcome of interest to this review.</P>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1. Measures of fat malabsorption</HEADING>
<P>Data were not reported in a way that allowed us to enter them into the meta-analysis. The abstract reported no significant difference in the percentage of fat absorbed and presented means and SDs for percentage of fat absorption with and without antacids (mean (SD) 65 (22)% and 66 (22)% respectively) (<LINK REF="STD-Lubin-1979" TYPE="STUDY">Lubin 1979</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-05-18 15:17:53 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Agents that reduce gastric acidity have been increasingly used as an adjunct to pancreatic enzymes in an attempt to improve nutritional status and gastro-intestinal symptoms in people with cystic fibrosis (CF). The effectiveness of long-term treatment is therefore of major clinical relevance. This review found 17 randomised controlled trials which examined the effects of drug therapies to reduce gastric acidity in people with CF. All the trials were single-centre trials and the duration of treatment was variable, ranging from five days to six months.</P>
<P>There were limitations to the review. The number of trials assessing different agents for reducing gastric acidity was small. Fourteen trials were of a cross-over design and we did not have the appropriate information to conduct comprehensive meta-analyses, but trial authors have been contacted for further information in order that a more complete analysis can be carried out. As has been described previously, the quality of the trials included within this review was generally not reported adequately. Therefore, we were unable to make firm conclusions based on the evidence that was reported in these trials.</P>
<P>Despite these difficulties, the review found limited evidence that drug therapies that reduce gastric acidity do improve fat absorption and may play a role in improving gastro-intestinal symptoms such as abdominal pain. Only one trial reported measures of respiratory function, while no trials reported details on various important outcomes such as quality of life, complications of increased gastric acidity and survival. Two trials studied the effects of different dosages of pancreatic enzymes in conjunction with an agent to reduce gastric acidity; the results of which were conflicting. There is very limited evidence in trials on children that there is benefit in improving fat absorption. From our review, no conclusive benefit of improved nutritional status and lung function can be deduced from the effects of agents that reduce gastric acidity. One trial reported an adverse effect with prostaglandin E2 analogue, misoprostol, which caused diarrhoea lasting longer than five days in two of the 22 participants in the treatment group (<LINK REF="STD-Robinson-1990" TYPE="STUDY">Robinson 1990</LINK>). Although results from this trial found significant improvement in fat malabsorption, these two participants were excluded from the analysis, which raises the question if there is any real benefit in this intervention.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-06-10 10:04:04 +0100" MODIFIED_BY="Nikki Jahnke">
<IMPLICATIONS_PRACTICE MODIFIED="2014-06-10 10:04:04 +0100" MODIFIED_BY="Nikki Jahnke">
<P>There is very limited evidence to suggest that agents that reduce gastric acidity in people with CF are associated with improvement in gastro-intestinal symptoms and fat absorption and due to the unclear risks of bias of the included trials, we are not able to draw firm conclusions on the evidence available. At present, there is insufficient evidence from randomised controlled trials to indicate whether there is an improvement in nutritional status, lung function, quality of life, or survival in people with CF treated with agents that reduce gastric acidity.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>This systematic review has identified the need for well-designed, adequately-powered, multicentred randomised controlled trials to assess the effects and possible adverse events associated with the use of agents that reduce gastric acidity in people with CF. Trials should be carried out over a longer duration to provide further information on long-term effects of lung function, quality of life measures to assess acceptability of treatment to people with CF and survival. If clear benefit is demonstrated, there will be a need for trials comparing different gastric reducing agents and assessing long-term outcomes. We would urge trialists to recognise that the results of individual randomised controlled trials are likely to be included in systematic reviews such as this. They should therefore consider standardising the presentation of outcomes to enable the data to be aggregated.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-07-25 11:56:53 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Many thanks to the Cochrane Cystic Fibrosis and Genetic Disorders Review Group, Dr P Wark and Professor R Smyth for their invaluable support and helpful comments. Thanks also to Angelo Francini who worked on previous versions of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-07-25 11:56:22 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Sze May Ng declares no potential conflict of interest.</P>
<P>Helen Moore declares no potential conflict of interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Both authors independently selected trials, assessed methodological quality and extracted data.</P>
<P>The lead author completed the write-up of the review and updates with contributions from the co-author and acts as guarantor of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2008-06-16 12:45:44 +0100" MODIFIED_BY="Nikki Jahnke"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-08-22 10:33:20 +0100" MODIFIED_BY="Nikki Jahnke">
<STUDIES MODIFIED="2016-07-21 15:00:21 +0100" MODIFIED_BY="Nikki Jahnke">
<INCLUDED_STUDIES MODIFIED="2016-07-21 15:00:21 +0100" MODIFIED_BY="Nikki Jahnke">
<STUDY DATA_SOURCE="PUB" ID="STD-Bowler-1993" MODIFIED="2008-07-07 12:19:21 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Bowler 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bowler IM, Wolfe SP, Littlewood JM, Chand R, McAllister J</AU>
<TI>CF patients with significant malabsorption: effects of a high lipase enzyme preparation and ranitidine [abstract]</TI>
<SO>Proceedings of the 18th European Cystic Fibrosis Conference; 1993; Madrid</SO>
<YR>1993</YR>
<PG>PD99</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845010"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845009"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boyle-1980" NAME="Boyle 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boyle BJ, Long WB, Balistreri WF, Widzer SJ, Huang N</AU>
<TI>Effect of cimetidine and pancreatic enzymes on serum and fecal bile acids and fat absorption in cystic fibrosis</TI>
<SO>Gastroenterology</SO>
<YR>1980</YR>
<VL>78</VL>
<NO>5 Pt 1</NO>
<PG>950-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845012"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845011"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carroccio-1992" NAME="Carroccio 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carroccio A, Pardo F, Montalto G, Iapichino L, Soresi M, Averna MR, et al</AU>
<TI>Use of famotidine in severe exocrine pancreatic insufficiency with persistent maldigestion on enzymatic replacement therapy: A long term study in cystic fibrosis</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>1992</YR>
<VL>37</VL>
<NO>9</NO>
<PG>1441-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845014"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845013"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chalmers-1985" MODIFIED="2014-03-25 10:51:26 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Chalmers 1985" YEAR="1985">
<REFERENCE MODIFIED="2014-03-25 10:48:46 +0000" MODIFIED_BY="Nikki Jahnke" NOTES="&lt;p&gt;Sze May Ng [01/09/2001][07/03/2003][]&lt;/p&gt;" NOTES_MODIFIED="2014-03-25 10:48:46 +0000" NOTES_MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Chalmers DM, Brown RC, Chir B, Miller MG, Clarke PCN, Kelleher J, et al</AU>
<TI>The influence of long-term cimetidine as an adjuvant to pancreatic enzyme therapy in cystic fibrosis[abstract]</TI>
<SO>12th Annual Meeting European Working Group for Cystic Fibrosis; 1983 Oct; Athens, Greece</SO>
<YR>1983</YR>
<PG>109-14</PG>
<IDENTIFIERS MODIFIED="2014-03-25 10:48:46 +0000" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER TYPE="CENTRAL" VALUE="291242"/><IDENTIFIER MODIFIED="2014-03-25 10:48:46 +0000" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="GN6a"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000001307"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845016"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-03-25 10:49:40 +0000" MODIFIED_BY="Nikki Jahnke" NOTES="&lt;p&gt;Sze May Ng [01/09/2001][07/03/2003][]&lt;/p&gt;" NOTES_MODIFIED="2014-03-25 10:49:40 +0000" NOTES_MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chalmers DM, Brown RC, Miller MG, Clarke PCN, Kelleher J, Littlewood JM, et al</AU>
<TI>Influence of long term cimetidine as an adjuvant to pancreatic enzyme therapy in cystic fibrosis [abstract]</TI>
<SO>Gut</SO>
<YR>1983</YR>
<VL>24</VL>
<PG>A978</PG>
<IDENTIFIERS MODIFIED="2014-03-25 10:49:39 +0000" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER TYPE="CENTRAL" VALUE="255539"/><IDENTIFIER MODIFIED="2014-03-25 10:49:39 +0000" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="GN6c"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000001162"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845017"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-03-25 10:51:26 +0000" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chalmers DM, Brown RC, Miller MG, Clarke PCN, Kelleher J, Littlewood JM, et al</AU>
<TI>The influence of long term cimetidine as an adjuvant to pancreatic enzyme therapy in cystic fibrosis</TI>
<SO>Acta Paediatrica Scandinavia</SO>
<YR>1985</YR>
<VL>74</VL>
<NO>1</NO>
<PG>114-7</PG>
<IDENTIFIERS MODIFIED="2014-03-25 10:51:26 +0000" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-03-25 10:51:26 +0000" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="GN6b"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845018"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845015"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chung-2000" NAME="Chung 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chung Y, Gunasekaran TS, Anst DB, Blue B, VanderBranden SV,</AU>
<TI>The impact of omeprazole on children with cystic fibrosis (CF) who require high dose pancreatic enzymes: A pilot study [abstract]</TI>
<SO>Journal of Pediatric Gastroenterology and Nutrition</SO>
<YR>2000</YR>
<VL>31</VL>
<NO>Suppl 2</NO>
<PG>S73</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845020"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845019"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DiMango-2014" MODIFIED="2016-07-21 15:00:21 +0100" MODIFIED_BY="Nikki Jahnke" NAME="DiMango 2014" YEAR="2012">
<REFERENCE MODIFIED="2016-05-18 13:05:31 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DiMango E, Walker P, Keating C, Berdella M, Robinson B, Langfelder-Schwind E, et al</AU>
<TI>Effect of proton pump inhibitors on cystic fibrosis (CF) pulmonary exacerbations in adults [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2012</YR>
<VL>47 Suppl 35</VL>
<PG>353, Abstract no: 362</PG>
<IDENTIFIERS MODIFIED="2016-05-18 13:05:31 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER TYPE="CENTRAL" VALUE="962121"/><IDENTIFIER MODIFIED="2016-05-18 13:05:31 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="GN235a"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500125000000039"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845022"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-07-21 14:57:07 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dimango E, Walker P, Keating C, Berdella M, Robinson N, Langfelder-Schwind E, et al</AU>
<TI>Effect of esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis</TI>
<SO>BMC Pulmonary Medicine</SO>
<YR>2014</YR>
<VL>14</VL>
<PG>21</PG>
<CY>England</CY>
<IDENTIFIERS MODIFIED="2016-05-18 13:06:20 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2016-05-18 13:06:20 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="GN235b"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000000427"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4356978"/><IDENTIFIER OTHERTYPE="GR:" TYPE="OTHER" VALUE="P30ES009089/ES/NIEHS NIH HHS/United States"/><IDENTIFIER OTHERTYPE="JID:" TYPE="OTHER" VALUE="100968563"/><IDENTIFIER OTHERTYPE="OID" TYPE="OTHER" VALUE="[Other ID]: NLM: PMC3931289"/><IDENTIFIER OTHERTYPE="PMCID:" TYPE="OTHER" VALUE="PMC3931289"/><IDENTIFIER TYPE="PUBMED" VALUE="24528942"/><IDENTIFIER OTHERTYPE="SI:" TYPE="OTHER" VALUE="ClinicalTrials.gov/NCT01983774"/><IDENTIFIER OTHERTYPE="UL1" TYPE="OTHER" VALUE="TR000040/TR/NCATS NIH HHS/United States"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-07-21 15:00:21 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845021"/><IDENTIFIER MODIFIED="2016-07-21 15:00:21 +0100" MODIFIED_BY="Nikki Jahnke" TYPE="CTG" VALUE="NCT01983774"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Durie-1980" NAME="Durie 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;20th Annual Meeting Cystic Fibrosis Club Abstracts; 1979 May 1; Atlanta, Georgia&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Durie PR, Bell L, Linton W, Corey ML, Crozier DN, Forstner GG</AU>
<TI>The effect of cimetidine and sodium bicarbonate on pancreatic replacement therapy in cystic fibrosis [abstract]</TI>
<SO>20th Annual Meeting Cystic Fibrosis Club Abstracts; 1979 May 1; Atlanta, Georgia</SO>
<YR>1979</YR>
<PG>37</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845024"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Durie PR, Bell L, Linton W, Corey ML, Forstner GG</AU>
<TI>Effect of cimetidine and sodium bicarbonate on pancreatic replacement therapy in cystic fibrosis</TI>
<SO>Gut</SO>
<YR>1980</YR>
<VL>21</VL>
<NO>9</NO>
<PG>778-86</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845025"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845023"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Francisco-2002" MODIFIED="2014-05-28 14:25:02 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Francisco 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-05-28 14:25:02 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Francisco MP, Wagner MH, Sherman JM, Theriiaque D, Bowser E, Novak DA</AU>
<TI>Ranitidine and omeprazole as adjuvant therapy to pancrealipase to improve fat absorption in patients with cystic fibrosis</TI>
<SO>Journal of Pediatric Gastroenterology and Nutrition</SO>
<YR>2002</YR>
<VL>35</VL>
<NO>1</NO>
<PG>79-83</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845027"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845026"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heijerman-1990" MODIFIED="2014-03-25 10:46:24 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Heijerman 1990" YEAR="1990">
<REFERENCE MODIFIED="2014-03-25 10:46:12 +0000" MODIFIED_BY="Nikki Jahnke" NOTES="&lt;p&gt;Sze May Ng [01/09/2001][07/03/2003][]&lt;/p&gt;" NOTES_MODIFIED="2014-03-25 10:46:12 +0000" NOTES_MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heijerman HG, Lamers CB, Dijkman JH, Bakker W</AU>
<TI>Ranitidine compared with the dimethylprostaglandin E2 analogue enprostil as adjunct to pancreatic enzyme replacement in adult cystic fibrosis</TI>
<SO>Scandinavian Journal of Gastroenterolology</SO>
<YR>1990</YR>
<VL>178</VL>
<NO>Suppl</NO>
<PG>26-31</PG>
<IDENTIFIERS MODIFIED="2014-03-25 10:46:12 +0000" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER TYPE="CENTRAL" VALUE="72775"/><IDENTIFIER MODIFIED="2014-03-25 10:46:12 +0000" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="GN13"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000000457"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845029"/><IDENTIFIER TYPE="PUBMED" VALUE="2126147"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845028"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heijerman-1991" NAME="Heijerman 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Heijerman HGM, Lamers CBHW, Bakker W</AU>
<TI>Omeprazole enhances the efficacy of pancreatin (pancrease) in cystic fibrosis</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1991</YR>
<VL>114</VL>
<NO>3</NO>
<PG>200-1</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845031"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Heijermann HGM, Lamers CBHW, Bakker W</AU>
<TI>Omeprazole enhances the efficacy of pancreatin (pancrease*) in cystic fibrosis [abstract]</TI>
<SO>Proceedings of the 17th European Cystic Fibrosis Conference; 1991 June 18-21; Copenhagen</SO>
<YR>1991</YR>
<PG>145</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845032"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845030"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heijerman-1993" NAME="Heijerman 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heijerman HGM, Lamers CBHW, Bakker W, Dijkman JH</AU>
<TI>Improvement of fecal fat excretion after addition of omeprazole to pancrease in cystic fibrosis is related to residual exocrine function of the pancreas</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>1993</YR>
<VL>38</VL>
<NO>1</NO>
<PG>1-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845034"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845033"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lubin-1979" MODIFIED="2010-04-21 11:17:26 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Lubin 1979" YEAR="1979">
<REFERENCE MODIFIED="2010-04-21 11:17:26 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lubin AH, Scott DH, Bonner JL</AU>
<TI>Failure of antacids to improve the effectiveness and/or utilization of pancreatic extracts in children with cystic fibrosis [abstract]</TI>
<SO>Proceedings of the 20th Annual Meeting Cystic Fibrosis Club Abstracts; 1979 May 1; Atlanta, Georgia</SO>
<YR>1979</YR>
<PG>57</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845036"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845035"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Proesmans-2003" MODIFIED="2014-03-25 10:55:06 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Proesmans 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-03-25 10:55:06 +0000" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Proesmans M, De Boeck K</AU>
<TI>Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes</TI>
<SO>European Journal of Pediatrics</SO>
<YR>2003</YR>
<VL>162</VL>
<NO>11</NO>
<PG>760-3</PG>
<IDENTIFIERS MODIFIED="2014-03-25 10:55:06 +0000" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER TYPE="CENTRAL" VALUE="474894"/><IDENTIFIER MODIFIED="2014-03-25 10:55:06 +0000" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="GN32"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000002575"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845038"/><IDENTIFIER TYPE="EMBASE" VALUE="2003465055"/><IDENTIFIER TYPE="PUBMED" VALUE="13680386"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845037"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robinson-1988" MODIFIED="2014-03-25 10:36:22 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Robinson 1988" YEAR="1988">
<REFERENCE MODIFIED="2014-03-25 10:35:50 +0000" MODIFIED_BY="Nikki Jahnke" NOTES="&lt;p&gt;Sze May Ng [01/09/2001][07/03/2003][]&lt;/p&gt;" NOTES_MODIFIED="2014-03-25 10:35:50 +0000" NOTES_MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robinson P, Smith A</AU>
<TI>Effect of misoprostol on malabsorption in cystic fibrosis [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1988</YR>
<VL>Suppl 2</VL>
<PG>148</PG>
<IDENTIFIERS MODIFIED="2014-03-25 10:35:50 +0000" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER TYPE="CENTRAL" VALUE="291544"/><IDENTIFIER MODIFIED="2014-03-25 10:35:50 +0000" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="GN14a"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000001560"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845040"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-03-25 10:36:22 +0000" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Robinson PJ, Sly PD, Smith AL</AU>
<TI>Effect of misoprostol on fat malabsorption in cystic fibrosis</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1988</YR>
<VL>63</VL>
<NO>9</NO>
<PG>1081-2</PG>
<IDENTIFIERS MODIFIED="2014-03-25 10:36:22 +0000" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-03-25 10:36:22 +0000" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="GN14b"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845041"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845039"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robinson-1990" NAME="Robinson 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robinson PJ, Sly PD</AU>
<TI>Placebo-controlled trial of misoprostol in cystic fibrosis</TI>
<SO>Journal of Pediatric Gastroenterology and Nutrition</SO>
<YR>1990</YR>
<VL>11</VL>
<NO>1</NO>
<PG>37-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845043"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845042"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schoni-1984" NAME="Schoni 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schoni M, Kraemer R, Ruedeberg A, Lentze M, Mordasini RC, Riesen WF, et al</AU>
<TI>Long term cimetidine in children with cystic fibrosis: a randomized double blind study</TI>
<SO>Pediatric Research</SO>
<YR>1984</YR>
<VL>18</VL>
<NO>1</NO>
<PG>66-70</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845045"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845044"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weber-1981" NAME="Weber 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Weber AM, Fontaine A, deGheldere B, Dufour OL, Bonin A, Roy CC</AU>
<TI>Enteric coated microspheres of sodium bicarbonate do not enhance the effectiveness of pancrease [abstract]</TI>
<SO>22nd Cystic Fibrosis Club Abstracts</SO>
<YR>1981</YR>
<PG>164</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845047"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845046"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-03-25 10:52:51 +0000" MODIFIED_BY="Nikki Jahnke">
<STUDY DATA_SOURCE="PUB" ID="STD-Ansaldi_x002d_Balocco-1988" NAME="Ansaldi-Balocco 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ansaldi-Balocco N, Santini B, Sarchi C</AU>
<TI>Efficacy of pancreatic enzyme supplementation in children with cystic fibrosis: Comparison of two preparations by random crossover study and a retrospective study of the same patients at two different ages</TI>
<SO>Journal of Pediatric Gastroenterology and Nutrition</SO>
<YR>1988</YR>
<VL>Suppl 1</VL>
<PG>S40-45</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845049"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845048"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cameron-1982" MODIFIED="2014-03-25 10:44:29 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Cameron 1982" YEAR="1982">
<REFERENCE MODIFIED="2014-03-25 10:44:29 +0000" MODIFIED_BY="Nikki Jahnke" NOTES="&lt;p&gt;Sze May Ng [01/09/2001][07/03/2003][]&lt;/p&gt;" NOTES_MODIFIED="2014-03-25 10:44:29 +0000" NOTES_MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cameron DJ, Pitcher Wilmott R, Milla PJ, More J, Ghale GK, Matthew DJ, et al</AU>
<TI>The effect of cimetidine on meal-stimulated gastric function and exogenous pancreatic enzymes in cystic fibrosis</TI>
<SO>Human Nutrition. Clinical Nutrition</SO>
<YR>1982</YR>
<VL>36</VL>
<NO>6</NO>
<PG>475-81</PG>
<IDENTIFIERS MODIFIED="2014-03-25 10:44:29 +0000" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER TYPE="CENTRAL" VALUE="30302"/><IDENTIFIER MODIFIED="2014-03-25 10:44:29 +0000" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="GN5"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000000165"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845051"/><IDENTIFIER TYPE="PUBMED" VALUE="6925576"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cameron DJ, Pitcher-Wilmott R, Milla PJ, More J, Ghale GK, Matthew DJ, et al</AU>
<TI>The effect of cimetidine on meals-stimulated gastric function and exogenous pancreatic enzymes in cystic fibrosis</TI>
<SO>Human Nutrition Clinical Nutrition</SO>
<YR>1982</YR>
<VL>36</VL>
<NO>6</NO>
<PG>475-81</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845052"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845050"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cox-1981" MODIFIED="2014-03-25 10:32:23 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Cox 1981" YEAR="1981">
<REFERENCE MODIFIED="2014-03-25 10:32:23 +0000" MODIFIED_BY="Nikki Jahnke" NOTES="&lt;p&gt;Sze May Ng [01/09/2001][07/03/2003][]&lt;/p&gt;" NOTES_MODIFIED="2014-03-25 10:32:23 +0000" NOTES_MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cox KL, Isenberg JN, Frates RC, Kramer RI, Prestidge CB, Goldman M</AU>
<TI>Effect of chronic cimetidine (C) administration on growth in cystic fibrosis (CF) patients [abstract]</TI>
<SO>22nd Annual Meeting Cystic Fibrosis Club Abstracts; 1981 May 1; San Francisco, California</SO>
<YR>1981</YR>
<PG>107</PG>
<IDENTIFIERS MODIFIED="2014-03-25 10:32:23 +0000" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER TYPE="CENTRAL" VALUE="291262"/><IDENTIFIER MODIFIED="2014-03-25 10:32:23 +0000" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="GN22"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000001327"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845054"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845053"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cucchiara-1996" NAME="Cucchiara 1996" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cucchiara S, Raia V, Minella R, Frezza T, De Vizia B, De Ritis G</AU>
<TI>Ultrasound measurement of gastric emptying time in patients with cystic fibrosis and effect of ranitidine on delayed gastric emptying</TI>
<SO>Journal of Pediatrics</SO>
<YR>1996</YR>
<VL>128</VL>
<NO>4</NO>
<PG>485-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845056"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845055"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dudley-1981" NAME="Dudley 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dudley F, McNeil S, Smith M</AU>
<TI>Malabsorption in cystic fibrosis: Failure to respond to cimetidine [abstract]</TI>
<SO>Australian and New Zealand Journal of Medicine</SO>
<YR>1981</YR>
<VL>11</VL>
<NO>2</NO>
<PG>223-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845058"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845057"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Francisco-1996" MODIFIED="2014-03-25 10:33:11 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Francisco 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-03-25 10:33:11 +0000" MODIFIED_BY="Nikki Jahnke" NOTES="&lt;p&gt;Sze May Ng [01/09/2001][07/03/2003][]&lt;/p&gt;" NOTES_MODIFIED="2014-03-25 10:33:11 +0000" NOTES_MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Francisco MP, Wagner M, Bowser E, Andres J</AU>
<TI>Comparison of 3-day Fat Balance Studies Performed at Home Versus in the CRC in Subjects with CF [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1996</YR>
<VL>Suppl 13</VL>
<PG>319</PG>
<IDENTIFIERS MODIFIED="2014-03-25 10:33:11 +0000" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER TYPE="CENTRAL" VALUE="291303"/><IDENTIFIER MODIFIED="2014-03-25 10:33:11 +0000" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="GN21"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000001361"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845060"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845059"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Geus-1999" NAME="Geus 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geus WP, Gan KH, Lamers CBHW, Heijerman HGM</AU>
<TI>Simultaneously measured duodenal and gastric pH in patients with cystic fibrosis: effect of omeprazole [abstract]</TI>
<SO>Netherlands Journal of Medicine</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>Suppl</NO>
<PG>S63</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845062"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845061"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gow-1981" NAME="Gow 1981" YEAR="1982">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gow R, Bradbear R, Francis P, Shepherd R</AU>
<TI>Comparative study of varying regimens to improve steatorrhoea and creatorrhoea in cystic fibrosis: Effectiveness of an enteric-coated preparation with and without antacids and cimetidine</TI>
<SO>The Lancet</SO>
<YR>1981</YR>
<VL>2</VL>
<NO>8255</NO>
<PG>1071-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845064"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shepherd RW , Gow R</AU>
<TI>Comparative trial of measures to prevent acid-peptic inactivation of pancreatic insufficiency due to cystic fibrosis</TI>
<SO>Australian and New Zealand Journal of Medicine</SO>
<YR>1982</YR>
<VL>12</VL>
<PG>106</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845065"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845063"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoffman-1987" NAME="Hoffman 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoffman RD, Isenberg JN, Powell GK</AU>
<TI>Carbohydrate malabsorption is minimal in school-age cystic fibrosis children</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>1987</YR>
<VL>32</VL>
<NO>10</NO>
<PG>1071-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845067"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845066"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kerr-1982" NAME="Kerr 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kerr JI, Alam MJ, Redmond OB, Buchanan KD</AU>
<TI>The role of maldigestion and gastric inhibitory polypeptide (GIP) in the defective insulin secretion in cystic fibrosis (CF) [abstract]</TI>
<SO>Proceedings of the 11th European Cystic Fibrosis Conference; Brussels, 1982</SO>
<YR>1982</YR>
<PG>208</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845069"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845068"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koletzo-1989" NAME="Koletzo 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Koletzko S, Corey M, Ellis L, Spino M, Durie J</AU>
<TI>Effects of cisapride in patients with cystic fibrosis (CF) and chronic distal intestinal obstruction syndrome (DIOS) [abstract]</TI>
<SO>Proceedings of the 3rd North American Cystic Fibrosis Conference; 1989 Oct 11-14; Florida</SO>
<YR>1989</YR>
<PG>138</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845071"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Koletzo S, Corey M, Ellis L, Spino M, Stringer DA, Durie P</AU>
<TI>Effects of cisapride in patients with cystic fibrosis and distal intestinal obstruction syndrome (DIOS)</TI>
<SO>Journal of Pediatrics</SO>
<YR>1990</YR>
<VL>117</VL>
<NO>5</NO>
<PG>815-22</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845072"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845070"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lloyd_x002d_Still-1992" MODIFIED="2008-07-07 12:20:08 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Lloyd-Still 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lloyd-Still JD, Powers C, West M, Bruer R, Hinkle M, Moran M</AU>
<TI>PGE1 in cystic fibrosis: lack of effect on fecal, serum and sweat electrolytes [abstract]</TI>
<SO>Proceedings of the 11th International Cystic Fibrosis Conference; 1992</SO>
<YR>1992</YR>
<PG>WP11</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845074"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845073"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maish-1998" MODIFIED="2014-03-25 10:52:51 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Maish 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-03-25 10:52:33 +0000" MODIFIED_BY="Nikki Jahnke" NOTES="&lt;p&gt;Sze May Ng [01/09/2001][07/03/2003][]&lt;/p&gt;" NOTES_MODIFIED="2014-03-25 10:52:33 +0000" NOTES_MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Maish WA, McCubbin MM, Letzig LG, Farrar IIIHC, Kearns GL</AU>
<TI>Pharmacokinetics of famotidine in patients with cystic fibrosis</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1998</YR>
<VL>38</VL>
<NO>11</NO>
<PG>1010-6</PG>
<IDENTIFIERS MODIFIED="2014-03-25 10:52:33 +0000" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER TYPE="CENTRAL" VALUE="157135"/><IDENTIFIER MODIFIED="2014-03-25 10:52:33 +0000" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="GN26b"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000000877"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845076"/><IDENTIFIER TYPE="PUBMED" VALUE="9824781"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-03-25 10:52:51 +0000" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maish WA, McCubbin MM, Letzig LG, Kearns GL</AU>
<TI>Famotidine (FAM) pharmacokinetics (PK) in patients with cystic fibrosis (CF) [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1997</YR>
<VL>Suppl 14</VL>
<PG>310</PG>
<IDENTIFIERS MODIFIED="2014-03-25 10:52:51 +0000" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-03-25 10:52:51 +0000" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="GN26a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845077"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845075"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1985" MODIFIED="2014-03-25 10:34:17 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Miller 1985" YEAR="1985">
<REFERENCE MODIFIED="2014-03-25 10:34:05 +0000" MODIFIED_BY="Nikki Jahnke" NOTES="&lt;p&gt;Sze May Ng [01/09/2001][07/03/2003][]&lt;/p&gt;" NOTES_MODIFIED="2014-03-25 10:34:05 +0000" NOTES_MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Miller MG, Walters MP, Chalmers DM, Kelleher J, Littlewood JM</AU>
<TI>The effect of the additional ranitidine to pancrease on duodenal contents in cystic fibrosis [abstract]</TI>
<SO>13th Annual Meeting of the European Working Group for Cystic Fibrosis; 1985 Nov 3-8; Jerusalem, Israel</SO>
<YR>1985</YR>
<PG>116</PG>
<IDENTIFIERS MODIFIED="2014-03-25 10:34:05 +0000" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER TYPE="CENTRAL" VALUE="291460"/><IDENTIFIER MODIFIED="2014-03-25 10:34:05 +0000" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="GN10"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000001489"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845079"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845078"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1986" NAME="Miller 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller MG, Chalmers DM, Littlewood JM, Kelleher J, Losowsky MS</AU>
<TI>Combined ranitidine and enteric coated microspheres (Pancrease) improves maldigestion in cystic fibrosis [abstract]</TI>
<SO>Gut</SO>
<YR>1986</YR>
<VL>27</VL>
<PG>A612</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845081"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845080"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mitchell-1981" NAME="Mitchell 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mitchell EA, Elliot RB</AU>
<TI>Failure of oral N-acetylcysteine to improve the malabsorption of cystic fibrosis</TI>
<SO>Australian Paediatric Journal</SO>
<YR>1981</YR>
<VL>17</VL>
<NO>3</NO>
<PG>207-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845083"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845082"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prinsen-1985" NAME="Prinsen 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prinsen JE, Thomas M</AU>
<TI>Cisapride in cystic fibrosis</TI>
<SO>The Lancet</SO>
<YR>1985</YR>
<VL>1</VL>
<NO>8427</NO>
<PG>512-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845085"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845084"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Santamaria-1989" NAME="Santamaria 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Santamaria F, Oggero V, Raia V, Salvatore D, Vittaria L, De Ritis G</AU>
<TI>Cisapride and cystic fibrosis [letter]</TI>
<SO>Journal of Pediatric Gastroenterology and Nutrition</SO>
<YR>1989</YR>
<VL>9</VL>
<NO>4</NO>
<PG>539</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845087"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845086"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1988" MODIFIED="2014-03-25 10:43:04 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Smith 1988" YEAR="1988">
<REFERENCE MODIFIED="2014-03-25 10:39:37 +0000" MODIFIED_BY="Nikki Jahnke" NOTES="&lt;p&gt;Sze May Ng [01/09/2001][07/03/2003][]&lt;/p&gt;" NOTES_MODIFIED="2014-03-25 10:39:37 +0000" NOTES_MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith HL, Handy DJ, Weller PH, Booth IW</AU>
<TI>Cisapride and cystic fibrosis [letter]</TI>
<SO>Lancet</SO>
<YR>1989</YR>
<VL>1</VL>
<NO>8633</NO>
<PG>338</PG>
<IDENTIFIERS MODIFIED="2014-03-25 10:39:37 +0000" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER TYPE="CENTRAL" VALUE="57876"/><IDENTIFIER MODIFIED="2014-03-25 10:39:37 +0000" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="GN11b"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000000377"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845089"/><IDENTIFIER TYPE="PUBMED" VALUE="2563500"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-03-25 10:42:05 +0000" MODIFIED_BY="Nikki Jahnke" NOTES="&lt;p&gt;Sze May Ng [01/09/2001][07/03/2003][]&lt;/p&gt;" NOTES_MODIFIED="2014-03-25 10:42:05 +0000" NOTES_MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith HL, Handy DJ, Weller PH, Booth IW</AU>
<TI>The effect of cisapride on gastrointestinal function in cystic fibrosis (CF) [abstract]</TI>
<SO>Excerpta Medica, Asia Pacific Congress Series, Proceedings of the 10th International Cystic Fibrosis Congress; 1988 March 5-10; Sydney</SO>
<YR>1988</YR>
<VL>74</VL>
<PG>G.I. (c)8</PG>
<IDENTIFIERS MODIFIED="2014-03-25 10:42:05 +0000" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER TYPE="CENTRAL" VALUE="291592"/><IDENTIFIER MODIFIED="2014-03-25 10:42:05 +0000" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="GN11a"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000001599"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845090"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845088"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stead-1988" NAME="Stead 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Stead RJ, Skypala I, Hodson ME</AU>
<TI>Enteric-coated microspheres of pancreatin versus non enteric-coated pancreatin combined with cimetidine in cystic fibrosis [abstract]</TI>
<SO>15th Annual Meeting of the European Working Group for Cystic Fibrosis; 1987; Oslo; Norway</SO>
<YR>1987</YR>
<PG>71</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845092"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Stead RJ, Skypala I, Hodson ME</AU>
<TI>Treatment of steatorrhoea in cystic fibrosis: a comparison of enteric-coated microspheres of pancreatin versus non-enteric-coated pancreatin and adjuvant cimetidine</TI>
<SO>Alimentary pharmacology &amp; therapeutics</SO>
<YR>1988</YR>
<VL>2</VL>
<NO>6</NO>
<PG>471-82</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845093"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845091"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsang-1994" MODIFIED="2010-04-21 11:13:28 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Tsang 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-04-21 11:13:28 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsang VT, Johnston A, Heritier F, Leaver N, Hodson ME, Yacoub M</AU>
<TI>Cyclosporin pharmacokinetics in heart-lung transplant recipients with cystic fibrosis. Effects of pancreatic enzymes and ranitidine</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1994</YR>
<VL>46</VL>
<NO>3</NO>
<PG>261-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845095"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845094"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zentler_x002d_Munro-1985" NAME="Zentler-Munro 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Zentler-Munro 1985&lt;br&gt;Zentler-Munro PL, Fine DR, Batten JC, Northfield TC. Effect of cimetidine on enzyme inactivation, bile acid precipitation, and lipid solubilisation in pancreatic steatorrhoea due to cystic fibrosis. Gut 1985; 26:892-901.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zentler-Munro PL, Fine DR, Batten JC, Northfield TC</AU>
<TI>Effect of cimetidine on enzyme inactivation, bile acid precipitation, and lipid solubilisation in pancreatic steatorrhoea due to cystic fibrosis</TI>
<SO>Gut</SO>
<YR>1985</YR>
<VL>26</VL>
<NO>9</NO>
<PG>892-901</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2845097"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2845096"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-05-18 15:14:33 +0100" MODIFIED_BY="Nikki Jahnke">
<ADDITIONAL_REFERENCES MODIFIED="2008-06-16 15:16:21 +0100" MODIFIED_BY="Nikki Jahnke">
<REFERENCE ID="REF-Bruno-1994" MODIFIED="2008-06-16 15:13:56 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Bruno 1994" TYPE="JOURNAL_ARTICLE">
<AU>Bruno MJ, Rauws EA, Hoek FJ, Tytgat GN</AU>
<TI>Comparative effects of adjuvant cimetidine and omeprazole during pancreatic enzyme replacement therapy</TI>
<SO>Digestive Disease and Science</SO>
<YR>1994</YR>
<VL>39</VL>
<NO>5</NO>
<PG>988-992</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CF-Foundation-1994" MODIFIED="2008-06-16 15:16:21 +0100" MODIFIED_BY="Nikki Jahnke" NAME="CF Foundation 1994" TYPE="OTHER">
<AU>CF Foundation</AU>
<TI>Annual Data Report</TI>
<SO>National Patient Registry</SO>
<YR>1994</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Curtin-2002" NAME="Curtin 2002" TYPE="JOURNAL_ARTICLE">
<AU>Curtin F, Altman DG, Elbourne D</AU>
<TI>Meta-analysis combining parallel and cross-over clinical trials. 1: Continuous outcomes</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>15</NO>
<PG>2131-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DiMagno-2001" MODIFIED="2008-06-16 15:14:17 +0100" MODIFIED_BY="Nikki Jahnke" NAME="DiMagno 2001" TYPE="JOURNAL_ARTICLE">
<AU>DiMagno EP</AU>
<TI>Gastric acid suppression and treatment of severe pancreatic exocrine insufficiency</TI>
<SO>Best Practice and Research in Clinical Gastroenterology</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>3</NO>
<PG>477-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-J_x00fc_ni-2001" NAME="Jüni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Jüni P, Altman DG, Egger M</AU>
<TI>Systematic reviews in health care: Assessing the quality of controlled clinical trials</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<NO>7303</NO>
<PG>42-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kraemer-1978" MODIFIED="2008-06-16 15:14:26 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Kraemer 1978" TYPE="JOURNAL_ARTICLE">
<AU>Kraemer R, Ruderberg A, Hodorn B, Rossi E</AU>
<TI>Relative underweight in cystic fibrosis and its prognostic value</TI>
<SO>Acta Paediatrica Scandinavica</SO>
<YR>1978</YR>
<VL>67</VL>
<NO>1</NO>
<PG>33-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murphy-1991" MODIFIED="2008-06-16 15:14:31 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Murphy 1991" TYPE="JOURNAL_ARTICLE">
<AU>Murphy JL, Wooton SA, Bond SA, Jackson AA</AU>
<TI>Energy content of stools in normal healthy controls and patients with cystic fibrosis</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1991</YR>
<VL>66</VL>
<NO>4</NO>
<PG>495-500</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Neijens-1985" MODIFIED="2008-06-16 15:14:36 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Neijens 1985" TYPE="JOURNAL_ARTICLE">
<AU>Neijens HJ, Duiverman EJ, Kerrebijn KF</AU>
<TI>Influence of respiratory exacerbations on lung function, variables on nutritional status in CF patients</TI>
<SO>Acta Paediatrica Scandinavica</SO>
<YR>1985</YR>
<VL>317 Suppl</VL>
<PG>38-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Regan-1979" MODIFIED="2008-06-16 15:14:46 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Regan 1979" TYPE="JOURNAL_ARTICLE">
<AU>Regan PT, Malagelada JR, Dimagno EP, Go VL</AU>
<TI>Reduced intraluminal bile acid concentrations and fat maldigestion in pancreatic insufficiency: Correction by treatment</TI>
<SO>Gastroenterology</SO>
<YR>1979</YR>
<VL>77</VL>
<NO>2</NO>
<PG>285-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weber-1984" NAME="Weber 1984" TYPE="JOURNAL_ARTICLE">
<AU>Weber AM, Roy CC</AU>
<TI>Intraduodenal events in cystic fibrosis</TI>
<SO>Journal of Pediatric Gastroenterology Nutrition</SO>
<YR>1984</YR>
<VL>3 Suppl</VL>
<PG>S113-9</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2016-05-18 15:14:33 +0100" MODIFIED_BY="Nikki Jahnke">
<REFERENCE ID="REF-Ng-2003" MODIFIED="2014-03-25 11:10:12 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Ng 2003" TYPE="COCHRANE_REVIEW">
<AU>Ng SM, Jones AP</AU>
<TI>Drug therapies for reducing gastric acidity in people with cystic fibrosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2014-03-25 11:07:50 +0000" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-03-25 11:07:50 +0000" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/14651858.CD003424"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ng-2012" MODIFIED="2014-03-25 11:09:39 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Ng 2012" TYPE="COCHRANE_REVIEW">
<AU>Ng SM, Francini AJ</AU>
<TI>Drug therapies for reducing gastric acidity in people with cystic fibrosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2014-03-25 11:09:39 +0000" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-03-25 11:09:39 +0000" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/14651858.CD003424.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ng-2014" MODIFIED="2016-05-18 15:14:33 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Ng 2014" TYPE="COCHRANE_REVIEW">
<AU>Ng SM, Franchini AJ</AU>
<TI>Drug therapies for reducing gastric acidity in people with cystic fibrosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2016-05-18 15:14:33 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2016-05-18 15:14:33 +0100" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/14651858.CD003424.pub3"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2016-05-18 13:05:11 +0100" MODIFIED_BY="Nikki Jahnke"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-07-25 11:53:40 +0100" MODIFIED_BY="Nikki Jahnke">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-07-25 11:53:40 +0100" MODIFIED_BY="Nikki Jahnke" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-05-28 14:13:47 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Bowler-1993">
<CHAR_METHODS MODIFIED="2014-05-28 14:09:40 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Randomised, double-blind, placebo-controlled cross-over trial.</P>
<P>3-arm trial for successive 2-week treatment periods.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-01 15:21:56 +0100" MODIFIED_BY="Nikki Jahnke">
<P>14 children with CF, mean age 11.9 years, age range 5.5 - 16.3 years.<BR/>Inclusion criteria: all receiving &gt; 30 pancreatic enzyme capsules a day and faecal fat output &gt; 15 g/day or fat absorption &lt; 85%.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-28 14:13:47 +0100" MODIFIED_BY="Nikki Jahnke">
<P>3 groups:<BR/>1. high-dose pancreatic enzyme (Creon®) and H2 receptor antagonist ranitidine;<BR/>2. high-dose pancreatic enzyme (Creon®) and placebo;<BR/>3. low-dose pancreatic enzyme and placebo.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Faecal fat output, stool weight.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-01 15:21:56 +0100" MODIFIED_BY="Nikki Jahnke">
<P>We were unable to include the results from the Bowler trial in the meta-analysis due to insufficient data.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-28 14:13:52 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Boyle-1980">
<CHAR_METHODS MODIFIED="2014-05-28 14:10:49 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Randomised cross-over trial, 2 groups for successive 5-day treatment periods (2-day equilibration and 3-day stool collection).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>8 people with CF, mean age 16 years, age range 12 - 25 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-28 14:13:52 +0100" MODIFIED_BY="Nikki Jahnke">
<P>2 groups:</P>
<P>1. pancreatic enzyme (Viokase®) alone;</P>
<P>2. pancreatic enzyme (Viokase®) plus the H2 receptor antagonist cimetidine .</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Faecal bile acids, weight and fat, and postprandial serum bile acids.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-01 15:22:32 +0100" MODIFIED_BY="Nikki Jahnke"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-28 14:14:02 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Carroccio-1992">
<CHAR_METHODS MODIFIED="2014-05-28 14:11:57 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Randomised, double-blind, placebo-controlled cross-over trial for 2 successive 6-month treatment periods.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-21 12:15:23 +0100" MODIFIED_BY="Nikki Jahnke">
<P>10 children with CF (7 males, 5 females), mean age 12.5 years, age range 7 - 18 years, with persistent steatorrhoea on enzymatic supplements (12 children were originally enrolled, but 2 were excluded).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-28 14:14:02 +0100" MODIFIED_BY="Nikki Jahnke">
<P>2 groups:</P>
<P>1. usual enzyme therapy plus famotidine 1 mg/kg/day;</P>
<P>2. usual enzyme therapy plus placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Faecal weight, fat absorption, weight and height changes, serum calcium, triglycerides, cholesterol, phosphate, iron, Hb, albumin, Crispin Norman score, Shwachman score.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-28 14:14:07 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Chalmers-1985">
<CHAR_METHODS MODIFIED="2014-05-28 14:12:33 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Randomised, double-blind, placebo-controlled cross-over trial for 2 successive 6-month periods.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>17 people with CF (7 males, 10 females) age range 5 - 19 years. Results reported from the 13 who gave adequate faecal samples.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-28 14:14:07 +0100" MODIFIED_BY="Nikki Jahnke">
<P>2 groups:</P>
<P>1. usual enzyme therapy plus cimetidine 25 mg/kg/day;</P>
<P>2. usual enzyme therapy plus placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Faecal fat, weight, nitrogen, bile acids, anthropometric measurements, bone age, peak flow, Crispin Norman score, Shwachman score, haemoglobin, albumin, calcium, creatinine and plasma vitamin A levels.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-01 10:58:24 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Chung-2000">
<CHAR_METHODS MODIFIED="2014-05-28 14:13:06 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Randomised double-blind placebo-controlled cross-over trial for 2 successive 6-week treatment periods with 1-week washout period.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-01 10:58:24 +0100" MODIFIED_BY="Nikki Jahnke">
<P>6 children with CF randomised, 1 excluded because of positive <I>H. pylori</I>. Data from 5 children aged 5 - 12 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-28 14:14:28 +0100" MODIFIED_BY="Nikki Jahnke">
<P>2 groups:</P>
<P>1. placebo;</P>
<P>2. omeprazole 10 mg/day or 20 mg/day depending on weight.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Faecal fat, CBC, SMAC, prealbumin, height, weight, malabsorption symptom checklist, genotype analysis, H. pylori status.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-25 11:52:28 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-DiMango-2014">
<CHAR_METHODS MODIFIED="2016-07-21 13:26:50 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Randomised, double-blind, placebo-controlled trial over 24 weeks; participants were evaluated every 8 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-25 11:52:28 +0100" MODIFIED_BY="Nikki Jahnke">
<P>21 people screened, 2 withdrew consent prior to randomisation, 2 were ineligible. 17 people (9 to active treatment, 8 to placebo) with CF, age &gt;18, of which 15 completed the trial.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-25 11:52:28 +0100" MODIFIED_BY="Nikki Jahnke">
<P>2 groups:</P>
<P>1. esomeprazole 40 mg 2x daily;</P>
<P>2. placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-25 11:52:28 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Primary outcome measure: time to first exacerbation (defined as initiation of treatment with IV or oral antibiotics for at least 7 days based on respiratory symptoms).</P>
<P>Secondary outcome measures included: assessment of CF related quality of life (CFQ-R); GSAS; exacerbation rate; and lung function.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-07-25 11:52:28 +0100" MODIFIED_BY="Nikki Jahnke">
<P>2 week run-in period prior to randomisation, during which all participants underwent 24-hour amublatory pH probe monitoring. Participants and investigators blinded to the results.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-28 14:22:49 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Durie-1980">
<CHAR_METHODS MODIFIED="2014-05-28 14:21:27 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Randomised cross-over trial of 4 periods of 7 days treatment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>21 people with CF, age range 10 - 17 years. 6 withdrawals: 2 voluntarily after 3 days; 3 on evidence of poor drug and diet compliance and inadequate stool collection; and 1 with a possible complication with cimetidine.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-28 14:22:49 +0100" MODIFIED_BY="Nikki Jahnke">
<P>4 groups:</P>
<P>1. pancreatic supplement (Pancrelipase, 27 capsules per day);</P>
<P>2. pancreatic supplement plus cimetidine (20 mg/kg body weight/24h);</P>
<P>3. pancreatic supplement plus sodium bicarbonate (15g/m2/24h);</P>
<P>4. pancreatic supplement plus cimetidine (20 mg/kg body weight/24h) and sodium bicarbonate (15g/m2/24h).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Faecal fat (gm/24 h and %)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-01 15:23:09 +0100" MODIFIED_BY="Nikki Jahnke"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-28 14:31:48 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Francisco-2002">
<CHAR_METHODS MODIFIED="2014-05-28 14:24:29 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Randomised double-blind placebo-controlled cross-over trial of 4 different 3-day treatment periods.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-07 12:10:23 +0100" MODIFIED_BY="Nikki Jahnke">
<P>22 participants: 10 adults with CF, aged 18 - 36 years; 12 children with CF aged 6 - 17 years. One adult dropped out of the study after completing 2 of the 4 treatment arms.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-28 14:31:48 +0100" MODIFIED_BY="Nikki Jahnke">
<P>4 treatment arms compared to placebo 2x daily:</P>
<P>1. children &lt; 40 kg - ranitidine 5 mg/kg;</P>
<P>2. children &lt; 40 kg - ranitidine 10 mg/kg;2.</P>
<P>3. children &gt; 40 kg and adults - ranitidine 150 mg </P>
<P>4. children &gt; 40 kg and adults - ranitidine 300 mg twice daily. </P>
<P>Adults also received omeprazole 20 mg daily as adjuvant therapy to pancreatic enzymes compared with placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Faecal fat absorption.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-28 14:33:23 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Heijerman-1990">
<CHAR_METHODS MODIFIED="2014-05-28 14:33:00 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Randomised, double-blind, placebo-controlled cross-over trial for 2 successive 14-day treatment periods.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>8 adults with CF (5 males, 3 females) mean age 28 years, range 21 - 43 years. 1 withdrawal during treatment period with enprostil because of severe diarrhoea and abdominal discomfort.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-28 14:33:23 +0100" MODIFIED_BY="Nikki Jahnke">
<P>2 groups:</P>
<P>1. oral ranitidine 2x 150 mg;</P>
<P>2. enprostil 2x 35 mcg as adjunct to Pancrease.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Faecal fat, weight, gastrointestinal symptoms.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-28 14:33:55 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Heijerman-1991">
<CHAR_METHODS>
<P>Randomised, double-blind. placebo-controlled cross-over trial with 4 successive 14-day treatment periods.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>9 adults with CF, mean age 29 years, age range 23 - 42 years. There were no withdrawals.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-28 14:33:55 +0100" MODIFIED_BY="Nikki Jahnke">
<P>4 consecutive 14-day treatment periods:<BR/>1. a high dose pancreatic enzyme, pancrelipase (Pancrease®) (4 capsules, 3 times daily) in conjunction with an oral proton pump inhibitor omeprazole 20 mg daily;<BR/>2. a high dose pancreatic enzyme, pancrelipase (Pancrease®) (4 capsules, 3 times daily) in conjunction with placebo;<BR/>3. a low dose pancreatic enzyme, pancrelipase (Pancrease®) (2 capsules, 3 times daily) in conjunction with an oral proton pump inhibitor omeprazole 20 mg daily;<BR/>4. a low dose pancreatic enzyme, pancrelipase (Pancrease®) (2 capsules, 3 times daily) in conjunction with placebo.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Faecal fat.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-28 14:35:45 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Heijerman-1993">
<CHAR_METHODS MODIFIED="2014-05-28 14:34:08 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Randomised, double-blind, placebo-controlled cross-over trial for successive 14-day treatment periods.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-06-16 14:57:30 +0100" MODIFIED_BY="Nikki Jahnke">
<P>11adults with CF (5 males, 6 females), age range 20 - 42 years. There were no withdrawals.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-28 14:35:45 +0100" MODIFIED_BY="Nikki Jahnke">
<P>2 groups: </P>
<P>1. pancrealipase plus placebo; </P>
<P>2. pancrealipase plus oral omeprazole 20 mg.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Faecal fat, serum trypsin, pancreatic polypeptide, insulin and gastrin, PABA in urine.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-01 11:22:57 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Lubin-1979">
<CHAR_METHODS MODIFIED="2014-05-28 14:36:07 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Parallel trial, single centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-28 14:36:08 +0100" MODIFIED_BY="Nikki Jahnke">
<P>12 children with CF.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-01 11:22:57 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Group 1: NaHCo<SUB>3</SUB> 10% solution, dose 15cc 1 hour after meals.<BR/>Group 2: CaCo<SUB>3</SUB> suspension, 1g/5cc, dose 5cc 1 hour after meals.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-28 14:36:10 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Mean fat absorption (%), serum calcium.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-28 14:36:12 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Only published as abstract.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-28 14:37:08 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Proesmans-2003">
<CHAR_METHODS>
<P>Randomised controlled cross-over trial. Not blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>24 participants were eligible for the study, of these 9 were excluded from the analysis. Results from 15 participants (12 boys and 3 girls), median age was 8.7 years (range 3.5 - 15.9 years).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-28 14:37:08 +0100" MODIFIED_BY="Nikki Jahnke">
<P>2 groups: </P>
<P>1. participants with less than 20 kg body weight were treated with 10 mg omeprazole daily; participants weighing more than 20 kg received 20 mg omeprazole daily;</P>
<P>2. no omeprazole.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Daily fat loss (g/day).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-01 15:21:16 +0100" MODIFIED_BY="Nikki Jahnke"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-28 14:38:08 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Robinson-1988">
<CHAR_METHODS MODIFIED="2014-05-28 14:37:37 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Randomised, double-blind, cross-over trial for 2 successive 14-day treatment periods.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-07 12:10:47 +0100" MODIFIED_BY="Nikki Jahnke">
<P>22 children with CF (18 males, 4 females) mean age 4.4 years, range 1.5 - 10.5 years. 2 children withdrew.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-28 14:38:08 +0100" MODIFIED_BY="Nikki Jahnke">
<P>2 groups:</P>
<P>1. pancrease 4x daily;</P>
<P>2. pancrease plus 100 mcg misoprostol 4x daily.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Faecal fat.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-01 15:23:51 +0100" MODIFIED_BY="Nikki Jahnke"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-28 14:39:16 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Robinson-1990">
<CHAR_METHODS MODIFIED="2014-05-28 14:38:26 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Randomised, double-blind, placebo-controlled cross-over trial for 2 successive 3-week treatment periods.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>17 children with CF (11 males, 6 females), mean age 6.2 years, range 0.5 - 13.8 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-28 14:39:16 +0100" MODIFIED_BY="Nikki Jahnke">
<P>2 groups: </P>
<P>1. usual enzyme therapy plus placebo 4x daily;</P>
<P>2. usual enzyme therapy plus misoprostol 100 mcg 4x daily.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Faecal fat.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-28 14:40:09 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Schoni-1984">
<CHAR_METHODS MODIFIED="2014-05-28 14:39:38 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Randomised, double-blind placebo-controlled trial over 4 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-07 12:11:04 +0100" MODIFIED_BY="Nikki Jahnke">
<P>38 children with CF (22 males, 16 females) mean age 12 years and 13.5 years respectively. Participants grouped according to acetylation phenotype (slow or fast) and matched according to their age before the trial. No withdrawals mentioned.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-28 14:40:09 +0100" MODIFIED_BY="Nikki Jahnke">
<P>2 groups:</P>
<P>1. cimetidine 600 mg/m<SUP>2</SUP> BSA; </P>
<P>2. placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical state, weight, height, skinfold thickness, lung function tests, PABA peptide test, plasma lipid and lipoprotein.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-28 14:41:07 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Weber-1981">
<CHAR_METHODS MODIFIED="2014-05-28 14:40:23 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Randomised, double-blind placebo-controlled cross-over trial for 2 successive 8-day treatment periods.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>18 children with CF, age range 3 - 13 years. No mention of withdrawals.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-28 14:41:07 +0100" MODIFIED_BY="Nikki Jahnke">
<P>2 groups:</P>
<P>1. sodium bicarbonate 1 mEq/kg/meal;</P>
<P>2. placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Faecal fat, chymotrypsin, bile acid, faecal weight.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BSA: body surface area<BR/>CBC: complete blood count<BR/>CF: cystic fibrosis<BR/>CFQ-R: cystic fibrosis questionnaire - revised<BR/>GSAS: gastroesophageal assessment score<BR/>Hb: haemoglobin<BR/>H. pylori: Helicobacter pylori<BR/>mEq: milliequivalent<BR/>PABA: para-aminobenzonic acid<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-04-21 11:14:25 +0100" MODIFIED_BY="Nikki Jahnke" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Ansaldi_x002d_Balocco-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial does not assess a gastric reducing supplement.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cameron-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is a non-randomised clinical controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cox-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is a non-randomised clinical cross-over trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-11 15:42:44 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Cucchiara-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-11 15:42:44 +0100" MODIFIED_BY="Nikki Jahnke">
<P>This is a randomised trial comparing cisapride (a pro-kinetic agent) and ranitidine (an agent that reduces gastric acidity). This does not fulfil the inclusion of trials criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dudley-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is a non-randomised clinical cross-over trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Francisco-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>This trial compares the accuracy of fat balance trials performed at home versus at a Clinical Research Centre.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-11 15:42:48 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Geus-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-11 15:42:48 +0100" MODIFIED_BY="Nikki Jahnke">
<P>This is a trial of gastric and duodenal pH. This does not fulfil the objective of the review. It is not a trial involving a gastric reducing agent.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-16 15:09:11 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Gow-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-16 15:09:11 +0100" MODIFIED_BY="Nikki Jahnke">
<P>This trial contained 4 treatment periods, 3 of which used interventions that were not relevant to the review, therefore no comparisons could be made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-11 15:42:54 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Hoffman-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-11 15:42:54 +0100" MODIFIED_BY="Nikki Jahnke">
<P>This is a trial of fecal excretion of carbohydrate compared to fat excretion in school-age cystic fibrosis children. This does not fulfil the objective of the review. It is not a trial involving a gastric reducing agent .</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-11 15:42:57 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Kerr-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-11 15:42:57 +0100" MODIFIED_BY="Nikki Jahnke">
<P>This trial measures gastric inhibitory polypeptide and insulin response in CF. This does not fulfil the objective of the review. It is not a trial involving a gastric reducing agent.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Koletzo-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>This trial assessed the effects of cisapride, which is a pro-kinetic agent and not an agent that reduces gastric acidity.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lloyd_x002d_Still-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is a non-randomised controlled clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-11 15:43:01 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Maish-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-11 15:43:01 +0100" MODIFIED_BY="Nikki Jahnke">
<P>This is a randomised trial comparing the pharmacokinetics between different modes of delivery of famotidine, that is oral versus intravenous route. This does not fulfil the objective of the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Miller-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is a non-randomised controlled clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-11 15:43:03 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Miller-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-11 15:43:03 +0100" MODIFIED_BY="Nikki Jahnke">
<P>This is a non-randomised clinical controlled trial looking at duodenal pH and lipase concentration. This does not fulfil the objective of the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-11 15:43:06 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Mitchell-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-11 15:43:06 +0100" MODIFIED_BY="Nikki Jahnke">
<P>This trial on N-acetylcysteine is not included because this is not an agent currently used to reduce gastric acidity. This does not fulfil the objective of the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Prinsen-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>This trial is on effects of cisapride which is a pro-kinetic agent and not an agent that reduces gastric acidity.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-11 15:43:09 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Santamaria-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-11 15:43:09 +0100" MODIFIED_BY="Nikki Jahnke">
<P>This trial is on effects of cisapride which is a pro-kinetic agent and not an agent that reduces gastric acidity. This does not fulfil the objective of the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-11 15:43:11 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Smith-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-11 15:43:11 +0100" MODIFIED_BY="Nikki Jahnke">
<P>This trial is on effects of cisapride which is a pro-kinetic agent and not an agent that reduces gastric acidity. This does not fulfil the objective of the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stead-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>This trial investigated the effects of enteric-coated microspheres of pancreatin compared with non-enteric-coated pancreatin combined with cimetidine. Enteric coated and non enteric coated pancreatin are not gastric reducing substances.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-21 11:14:25 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Tsang-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-21 11:14:25 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Trial looking at the immunosuppressant cyclosporin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-11 15:43:14 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Zentler_x002d_Munro-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-11 15:43:14 +0100" MODIFIED_BY="Nikki Jahnke">
<P>This trial assessed lipase, bile acid and trypsin concentration. This does not fulfil the objective of the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-07-25 11:53:40 +0100" MODIFIED_BY="Nikki Jahnke">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-07-25 11:53:31 +0100" MODIFIED_BY="Nikki Jahnke" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-16 14:37:52 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Bowler-1993">
<DESCRIPTION>
<P>Described as randomised, but no details of method given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-16 14:38:02 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Boyle-1980">
<DESCRIPTION>
<P>Described as randomised, but no details of method given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-16 14:38:04 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Carroccio-1992">
<DESCRIPTION>
<P>Described as randomised, but no details of method given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-16 14:38:06 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Chalmers-1985">
<DESCRIPTION>
<P>Described as randomised, but no details of method given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-16 14:38:08 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Chung-2000">
<DESCRIPTION>
<P>Described as randomised, but no details of method given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-25 11:53:31 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-DiMango-2014">
<DESCRIPTION>
<P>Described as randomised, but no details of method given. Used a 1:1 ratio of treatment to placebo regardless of pH probe results, stratified by study centre and FEV<SUB>1</SUB> decile.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-16 14:38:12 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Durie-1980">
<DESCRIPTION>
<P>Described as randomised, but no details of method given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-16 14:38:14 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Francisco-2002">
<DESCRIPTION>
<P>Described as randomised, but no details of method given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-16 14:38:16 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Heijerman-1990">
<DESCRIPTION>
<P>Described as randomised, but no details of method given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-16 14:38:18 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Heijerman-1991">
<DESCRIPTION>
<P>Described as randomised, but no details of method given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-16 14:38:20 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Heijerman-1993">
<DESCRIPTION>
<P>Described as randomised, but no details of method given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-21 11:29:41 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Lubin-1979">
<DESCRIPTION>
<P>States participants randomly allocated, but no details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-16 14:38:22 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Proesmans-2003">
<DESCRIPTION>
<P>Described as randomised, but no details of method given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-16 14:38:24 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-1988">
<DESCRIPTION>
<P>Described as randomised, but no details of method given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-16 14:38:26 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-1990">
<DESCRIPTION>
<P>Described as randomised, but no details of method given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-16 14:38:28 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Schoni-1984">
<DESCRIPTION>
<P>Described as randomised, but no details of method given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-16 14:38:29 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Weber-1981">
<DESCRIPTION>
<P>Described as randomised, but no details of method given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-07-25 11:53:37 +0100" MODIFIED_BY="Nikki Jahnke" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:08:01 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Bowler-1993">
<DESCRIPTION>
<P>Not discussed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:08:41 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Boyle-1980">
<DESCRIPTION>
<P>Not discussed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:09:06 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Carroccio-1992">
<DESCRIPTION>
<P>Not discussed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:09:38 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Chalmers-1985">
<DESCRIPTION>
<P>Not discussed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 10:36:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chung-2000">
<DESCRIPTION>
<P>Not discussed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-25 11:53:37 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-DiMango-2014">
<DESCRIPTION>
<P>Colombia University Research Pharmacy prepared study medications.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:10:15 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Durie-1980">
<DESCRIPTION>
<P>Not discussed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:10:24 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Francisco-2002">
<DESCRIPTION>
<P>Not discussed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:10:31 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Heijerman-1990">
<DESCRIPTION>
<P>Not discussed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:10:35 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Heijerman-1991">
<DESCRIPTION>
<P>Not discussed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:10:40 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Heijerman-1993">
<DESCRIPTION>
<P>Not discussed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-21 11:30:47 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Lubin-1979">
<DESCRIPTION>
<P>Not discussed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:10:43 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Proesmans-2003">
<DESCRIPTION>
<P>Not discussed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:10:48 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-1988">
<DESCRIPTION>
<P>Not discussed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-16 15:03:17 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Robinson-1990">
<DESCRIPTION>
<P>Randomisation carried out at the pharmacy in the hospital.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:11:05 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Schoni-1984">
<DESCRIPTION>
<P>Not discussed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:11:08 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Weber-1981">
<DESCRIPTION>
<P> Not discussed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-05-18 20:33:10 +0100" MODIFIED_BY="Nikki Jahnke" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 12:08:24 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Bowler-1993">
<DESCRIPTION>
<P>Described as double-blind in text but no further details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-03 10:26:15 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Boyle-1980">
<DESCRIPTION>
<P>Did not report blinding of investigators.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 12:09:14 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Carroccio-1992">
<DESCRIPTION>
<P>Described as double-blind in text but no further details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 12:09:45 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Chalmers-1985">
<DESCRIPTION>
<P>Described as double-blind in text but no further details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 12:10:05 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Chung-2000">
<DESCRIPTION>
<P>Described as double-blind in text but no further details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-18 20:33:10 +0100" MODIFIED_BY="Angelo Franchini" RESULT="UNKNOWN" STUDY_ID="STD-DiMango-2014">
<DESCRIPTION>
<P>Not discussed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-16 14:51:37 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Durie-1980">
<DESCRIPTION>
<P>Level of blinding not discussed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 12:10:26 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Francisco-2002">
<DESCRIPTION>
<P>Described as double-blind, but no further details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 12:10:32 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Heijerman-1990">
<DESCRIPTION>
<P>Described as double-blind in text but no details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 12:10:36 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Heijerman-1991">
<DESCRIPTION>
<P>Described as double-blinded in text but no details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 12:10:40 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Heijerman-1993">
<DESCRIPTION>
<P>Described as double-blinded in text but no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-04-21 11:30:48 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Lubin-1979">
<DESCRIPTION>
<P>Not discussed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 12:10:44 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="NO" STUDY_ID="STD-Proesmans-2003">
<DESCRIPTION>
<P>Not blinded (treatment versus nothing).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 12:10:50 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-1988">
<DESCRIPTION>
<P>Described as double-blinded in text but no further details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-04-01 15:24:13 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-1990">
<DESCRIPTION>
<P>Described as double-blinded, participants each given 2 bottles of identical looking medication at start of trial (1 bottle of active misoprostol and 1 bottle of inert placebo).</P>
<P>Parents of 5 out of 15 children were reported to be able to identify the misoprostol treatment period by improvements in symptoms such as abdominal pain and bulky bowel movements.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 12:11:06 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Schoni-1984">
<DESCRIPTION>
<P>Described as double-blinded in text but no further details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 12:18:49 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Weber-1981">
<DESCRIPTION>
<P>Described as double-blinded in text but no further details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-07-25 11:53:40 +0100" MODIFIED_BY="Nikki Jahnke" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-16 14:41:38 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="NO" STUDY_ID="STD-Bowler-1993">
<DESCRIPTION>
<P>Discrepancy between the number of participants entering and completing the trial which was not addressed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-07 12:08:56 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Boyle-1980">
<DESCRIPTION>
<P>Stool collection from 1 participant was not complete, so stool data based on 7 participants only.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-07 12:09:18 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Carroccio-1992">
<DESCRIPTION>
<P>12 children were originally enrolled, but 2 were excluded with severe pulmonary infections.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-07 12:09:51 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Chalmers-1985">
<DESCRIPTION>
<P>At 10 months 1 participant withdrew from group originally assigned to cimetidine (withdrew whilst taking placebo) due to deterioration in respiratory function. This left 8 participants in each group. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-07 12:10:12 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Chung-2000">
<DESCRIPTION>
<P>1 child excluded because of positive H. pylori, data available from 5 remaining participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-25 11:53:40 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-DiMango-2014">
<DESCRIPTION>
<P>1 loss to follow-up in esomeprazole arm (moved), 1 discontinued in placebo arm because of lung transplantation. For participants withdrawn after randomisation, longitudinal analyses compared each value at the start of the treatment period to the last observed value carried forward for each variable.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-07 12:10:17 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Durie-1980">
<DESCRIPTION>
<P>6 withdrawals: 2 voluntarily after 3 days; 3 on evidence of poor drug and diet compliance and inadequate stool collection; and 1 with a possible complication with cimetidine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-07 12:10:30 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Francisco-2002">
<DESCRIPTION>
<P>One adult dropped out of the study after completing 2 of the 4 treatment arms. For 12 of the 96 admissions (12.5%) recognisable errors were made in the protocol. Analyses were performed including and excluding these admissions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-07 12:10:34 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Heijerman-1990">
<DESCRIPTION>
<P>1 withdrawal during treatment period with enprostil because of severe diarrhoea and abdominal discomfort.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-07 12:10:38 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Heijerman-1991">
<DESCRIPTION>
<P>9 participants randomised, data for all 9 presented, therefore there were no withdrawals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-07 12:10:42 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Heijerman-1993">
<DESCRIPTION>
<P>11 participants randomised, data for 11 participants presented, therefore there were no withdrawals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-04-21 11:30:48 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Lubin-1979">
<DESCRIPTION>
<P>No withdrawals described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-07 12:18:09 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Proesmans-2003">
<DESCRIPTION>
<P>24 participants were eligible for the study, of these 9 were excluded from the analysis (1 had viral illness during stool collection while taking omeprazole; in 8 participants residual fat loss could not be confirmed in stool collection when not taking omeprazole). Results from 15 participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-07 12:10:53 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Robinson-1988">
<DESCRIPTION>
<P>2 participants withdrawn due to protracted diarrhoea, 20 completed study. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-07-01 11:26:26 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Robinson-1990">
<DESCRIPTION>
<P>2 withdrawals, 1 aged 6 months due to marked diarrhoea while taking misoprostol and 1 because of poor compliance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-03 15:11:13 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Schoni-1984">
<DESCRIPTION>
<P>No withdrawals mentioned. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-03 15:11:19 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Weber-1981">
<DESCRIPTION>
<P>No mention of withdrawals. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-05-12 10:37:32 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-05-12 10:37:32 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-05-18 15:16:51 +0100" MODIFIED_BY="Nikki Jahnke"/>
<FIGURES MODIFIED="2008-07-03 15:23:24 +0100" MODIFIED_BY="Nikki Jahnke"/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>